WO2013185116A1 - Lipids for therapeutic agent delivery formulations - Google Patents

Lipids for therapeutic agent delivery formulations Download PDF

Info

Publication number
WO2013185116A1
WO2013185116A1 PCT/US2013/044849 US2013044849W WO2013185116A1 WO 2013185116 A1 WO2013185116 A1 WO 2013185116A1 US 2013044849 W US2013044849 W US 2013044849W WO 2013185116 A1 WO2013185116 A1 WO 2013185116A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
dcm
diyl
ethane
bis
Prior art date
Application number
PCT/US2013/044849
Other languages
French (fr)
Inventor
Joseph E. Payne
John A. GAUDETTE
Zheng Hou
Mohammad Ahmadian
Lei Yu
Victor Knopov
Violetta AKOPIAN
Priya Karmali
Richard P. WITTE
Neda SAFARZADEH
Wenbin Ying
Jun Zhang
Original Assignee
Payne Joseph E
Gaudette John A
Zheng Hou
Mohammad Ahmadian
Lei Yu
Victor Knopov
Akopian Violetta
Priya Karmali
Witte Richard P
Safarzadeh Neda
Wenbin Ying
Jun Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL18200656T priority Critical patent/PL3489220T3/en
Priority to DK13729241.3T priority patent/DK2858974T3/en
Application filed by Payne Joseph E, Gaudette John A, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Akopian Violetta, Priya Karmali, Witte Richard P, Safarzadeh Neda, Wenbin Ying, Jun Zhang filed Critical Payne Joseph E
Priority to CN201380041854.8A priority patent/CN104640841B/en
Priority to LTEP13729241.3T priority patent/LT2858974T/en
Priority to RS20181385A priority patent/RS58108B9/en
Priority to ES13729241T priority patent/ES2697680T3/en
Priority to SI201331245T priority patent/SI2858974T1/en
Priority to CA2876148A priority patent/CA2876148C/en
Priority to BR112014030714-8A priority patent/BR112014030714B1/en
Priority to AU2013270685A priority patent/AU2013270685B2/en
Priority to EP13729241.3A priority patent/EP2858974B9/en
Priority to EP18200656.9A priority patent/EP3489220B9/en
Priority to JP2015516267A priority patent/JP5873604B2/en
Priority to PL13729241T priority patent/PL2858974T3/en
Priority to KR1020157000454A priority patent/KR102102801B1/en
Priority to RU2014153658A priority patent/RU2658007C2/en
Publication of WO2013185116A1 publication Critical patent/WO2013185116A1/en
Priority to HRP20181855TT priority patent/HRP20181855T1/en
Priority to CY181101255T priority patent/CY1120929T1/en
Priority to CY20211100818T priority patent/CY1124499T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer

Definitions

  • the description is directed to ionizable lipids for enhancing the delivery of therapeutic agents.
  • Non-viral transfection systems can include, for example, polymers, lipids, liposomes, micelles, dendrimers, and nanomaterials.
  • Polymers that have been studies for cell transfection include cationic polymers such as, for example, poly(L-lysine) ("PLL"), polyethyleneimine (“PEI”), chitosan, and poly(2-dimethylamino)ethyl methacrylate
  • viral and non- viral transfection techniques have drawbacks, however.
  • viral systems can yield high transfection efficiency, but may not be entirely safe.
  • viral systems can be complicated and/or expensive to prepare.
  • Non-viral transfection systems for example, those employing cationic polymers, have been reported to transfer plasmid DNA into cells.
  • Cationic polymers however, can be unstable and can be toxic to cells.
  • Cio-18 alkyl or C 12-1 8 alkenyl is -CH 2 -, S, O, N, or absent;
  • L is C 1-4 alkylene; -S-C 1-4 alkylene; -
  • compositions, pharmaceutical formulations, drug carriers, and methods of using the compounds of formula I are also described.
  • FIG. 1 depicts in vitro synergistic efficacy of ionizable lipid:ionizable lipid embodiments of the present description
  • FIG. 2 depicts in vitro synergistic efficacy of ionizable lipid:ionizable lipid embodiments of the present description
  • FIG. 3 depicts in vitro synergistic efficacy of ionizable lipid: cationic lipid embodiments of the present description
  • FIG. 4 depicts in vivo efficacy of ionizable lipid: cationic lipid embodiments of the present description
  • the present description is directed to ionizable lipid compounds, as well as their uses in delivering therapeutic agents to cells, tissues, and organisms.
  • n and m are independently 1, 2, 3, or 4;
  • Ri and R 2 are independently Cio-is alkyl or C 12-18 alkenyl
  • X is -CH 2 -, S, O, N, or absent;
  • L is Ci-4 alkylene; -S-C 1-4 alkylene; -0-C 1-4 alkylene; -0-C(0)-Ci
  • n and m can be the same or different. In preferred embodiments, n and m are the same. Particularly preferred are those embodiments wherein n and m are both 1 or n and m are both 2.
  • X is a bond. In other embodiments, X is -CH 2 -. In still others, X is S. Also preferred, are embodiments wherein X is O. Embodiments wherein X is N are also within the scope of the description.
  • L is C 1-4 alkylene.
  • L is
  • L is -S-Ci-4 alkylene. In yet other embodiments, L is -O-C1-4 alkylene. In still other embodiments, L is
  • L is -S(0) 2 -C 1-4 alkylene. Also within the scope of the description are embodiments wherein L is
  • L is preferably C 1-4 alkylene.
  • L include -CH 2 -, -CH 2 -CH 2 -, -CH 2 CH 2 CH 2 -, and -CH 2 CH 2 CH 2 CH 2 -.
  • L is S C-
  • X is -CH 2 -
  • L is preferably -S-C 1-4 alkylene.
  • L include -S-CH 2 -, -S-CH 2 -CH 2 -, -S-CH 2 CH 2 CH 2 -, and -S-CH 2
  • L is preferably -S(0) 2 -C 1-4 alkylene.
  • L include -S(0) 2 -CH 2 , -S(0) 2 -CH 2 -CH 2 , -S(0) 2 -CH 2 -CH 2 -, and S(0) 2 -CH 2 -CH 2 -CH 2 -CH 2 -.
  • L is -0-C 1-4 alkylene.
  • L include -0-CH 2 -, -0-CH 2 -CH 2 -, -0-CH 2 CH 2 CH 2 -, and -0-CH 2 CH 2 CH 2 CH 2 -.
  • L is preferably Ci_ 4 alkylene.
  • L include -CH 2 -, -CH 2 -CH 2 -, -CH 2 CH 2 CH 2 -, and -CH 2
  • L is preferably C 1-4 alkylene.
  • L include -CH 2 -, -CH 2 -CH 2 -, -CH 2 CH 2 CH 2 -, and -CH 2 CH 2 CH 2 CH 2 -.
  • Ri and R 2 can be the same or different.
  • Ri and R 2 are the same.
  • Ri and R 2 are Cw-is alkyl.
  • the Cio-is alkyl is a straight-chain C 10 -i 8 alkyl. More preferred are embodiments wherein Ri and R 2 are C 12-18 alkyl. Also preferred are embodiments wherein Ri and R 2 are
  • Ri and R 2 are both C 13 alkyl.
  • Ri and R 2 are C 12-18 alkenyl.
  • Ri and R 2 are and R 2 are each oleyl:
  • Ri and R 2 are C 12-18 alkenyl.
  • Ri and R 2 are C 13- linoleoyl.
  • compositions comprising a compound of formula I in a liposome, wherein the liposome comprises a bilayer of lipid molecules.
  • the compound of formula I can comprise any mole percentage of the lipid molecules in such compositions, it is preferred that the compound of formula I is about 5 to about 50 mol % of the lipid molecules of the compositions of the description.
  • compositions of the description comprising a compound of formula I in a liposome can contain more than one compound of formula I.
  • such compositions of the description include two compounds of formula I.
  • it is preferred that the molar ratio of the two compounds of formula I is about 10:30 to about 30: 10.
  • compositions of the description comprising a compound of formula I in a liposome may further comprise a cationic lipid.
  • the cationic lipid is about 5 to about 40 mol % of the lipid molecules of the composition.
  • the molar ratio of the compound of formula I to the cationic lipid is about 5:35 to about 35:5. More preferable, the ratio is about 10:30 to about 30: 10.
  • any compositions of the description may further comprise a liquid medium.
  • the liquid medium is suitable for injection into a living organism.
  • the liquid medium comprises an organic solvent.
  • the liquid medium used in certain embodiments of the description comprises water and an organic solvent.
  • the liquid medium may further comprise a non-aqueous medium.
  • compositions of the description may further comprise at least one phospholipid.
  • any compositions of the description may further comprise at least one PEG-conjugated lipid.
  • the drug carriers of the description will further comprising a siRNA molecule.
  • compositions within the scope of the description include any of the
  • the siRNA is encapsulated by the liposome of the compositions of the description.
  • kits for delivering a drug to a patient in need of treatment comprise providing a pharmaceutical formulation within the scope of the description and administering the pharmaceutical formulation to the patient.
  • cationic lipid refers to a compound that includes at least one lipid moiety and a positively charged quaternary nitrogen associated with a counterion.
  • Lipids are understood in the art to be comprises of a hydrophobic alkyl or alkenyl moiety and a carboxylic acid or ester moiety. Preferred cationic lipids for use in the present description include:
  • ionizable lipid refers to a compound of formula I within the scope of the description. These compounds are capable of forming charged species when contacted with an appropriate counterion species, for example, a species that includes an ionizable hydrogen atom.
  • alkyl refers to a straight or branched fully saturated (no double or triple bonds) hydrocarbon group, for example, a group having the general formula - C n H2 n+1 .
  • the alkyl group may have 1 to 50 carbon atoms (whenever it appears herein, a numerical range such as “1 to 50” refers to each integer in the given range; e.g., "1 to 50 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 50 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated).
  • the alkyl group may also be a medium size alkyl having 1 to 30 carbon atoms.
  • the alkyl group could also be a lower alkyl having 1 to 5 carbon atoms.
  • the alkyl group of the compounds may be designated as "C 1-4 alkyl” or similar designations.
  • “C 1-4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec -butyl, and t-butyl.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like.
  • alkylene refers to an alkanediyl functional group, for example, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and the like.
  • alkenyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds.
  • An alkenyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution unless otherwise indicated.
  • Oleyl is an example of such an alkenyl group.
  • DMSO dimethyl sulfoxide
  • the term "diluent” refers to chemical compounds diluted in water that will dissolve the formulation of interest (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) as well as stabilize the biologically active form of the formulation.
  • Salts dissolved in buffered solutions are utilized as diluents in the art.
  • One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of the formulation.
  • an “excipient” refers to an inert substance that is added to a formulation to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability, etc., to the composition.
  • a “diluent” is a type of excipient.
  • Organic solvents used within the scope of the description are known in the art, per se. and include, for example, alcohols, dimethyl sulfoxide (“DMSO”), and the like.
  • therapeutic agent refers to a compound that, upon activation of a cell or tissue.
  • a therapeutic agent may be referred to herein as a drug.
  • a therapeutic agent is not limited to drugs that have received regulatory approval.
  • a “therapeutic agent” can be operatively associated with a compound as described herein, a retinoid, and/or a second lipid.
  • a second lipid as described herein can form a liposome, and the therapeutic agent can be operatively associated with the liposome, e.g., as described herein.
  • retinoid is a member of the class of compounds consisting of four isoprenoid units joined in a head-to-tail manner, see G. P. Moss, "Biochemical
  • retinoid refers to natural and synthetic retinoids including first generation, second generation, and third generation retinoids. Examples of naturally occurring retinoids include, but are not limited to, (1) 1 1-cis-retinal, (2) all-trans retinol, (3) retinyl palmitate, (4) all- trans retinoic acid, and (5) 13-cis-retinoic acids. Furthermore, the term "retinoid” encompasses retinols, retinals, retinoic acids, retinoids, and derivatives thereof.
  • retinoid conjugate refers to a molecule that includes at least one retinoid moiety.
  • the retinoid conjugate will be present at a concentration of about 0.3 to about 30 weight percent, based on the total weight of the composition or formulation, which is equivalent to about 0.1 to about 10 mol.%, which is equivalent to a molar ratio of about 0.1 to about 10.
  • the retinoid conjugate is a retinoid-linker-lipid molecule or a retinoid-linker-retinoid molecule.
  • retinoid conjugates include those compounds of formula II:
  • q, r, and s are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and enantiomers and diastereomers thereof.
  • Preferred compounds of formula II include those wherein q, r, and s are each independently 1, 2, 3, 4, 5, 6, or 7. More preferred are those compounds of formula II wherein q, r, and s are each independently 3, 4, or 5. Most preferred are those compounds of formula II wherein q is 3, r is 5, and s is 3.
  • One example of a compound of formula II is
  • DiVA-PEG-DiVA includes stereocenters and all enantiomers and diastereomers are considered to be within the scope of the description.
  • retinoid-linker-lipid molecule refers to a molecule that includes at least one retinoid moiety attached to at least one lipid moiety through at least one linker such as, for example, a PEG moiety.
  • retinoid linker-retinoid molecule refers to a molecule that includes at least one retinoid moiety attached to at least one other retinoid moiety (which may be the same or different) through at least one linker such as, for example, a PEG moiety.
  • lipid and lipophilic are used herein in their ordinary meanings as understood by those skilled in the art.
  • Non-limiting examples of lipids and lipophilic groups include fatty acids, sterols, C2-C50 alkyl, C2-C50 heteroalkyl, C2-C50 alkenyl, C2-C50 heteroalkenyl, C2-C50 aryl, C2-C50 heteroaryl, C2-C50 alkynyl, C2-C50 heteroalkynyl, C2-C50 carboxyalkenyl, and C2-C50 carboxyheteroalkenyl.
  • a fatty acid is a saturated or unsaturated long-chain monocarboxylic acid that contains, for example, 12 to 24 carbon atoms
  • a lipid is characterized as being essentially water insoluble, having a solubility in water of less than about 0.01% (weight basis).
  • the terms "lipid moiety” and "lipophilic moiety” refers to a lipid or portion thereof that has become attached to another group.
  • a lipid group may become attached to another compound (e.g., a monomer) by a chemical reaction between a functional group (such as a carboxylic acid group) of the lipid and an appropriate functional group of a monomer.
  • tellate cell refers to neurons with several dendrites radiating from the cell body. Examples of stellate cells are inhibitory interneurons.
  • siRNA refers to small interfering RNA, also known in the art as short interfering RNA or silencing RNA. siRNA is a class of double stranded RNA molecules that have a variety of effects known in the art, the most notable being the interference with the expression of specific genes and protein expression.
  • the term "liposome” is used herein in its ordinary meaning as understood by those skilled in the art, and refers to a lipid bilayer structure that contains lipids attached to polar, hydrophilic groups which form a substantially closed structure in aqueous media. In some embodiments, the liposome can be operatively associated with one or more compounds, such as a therapeutic agent and a retinoid.
  • a liposome may be comprised of a single lipid bilayer (i.e., unilamellar) or it may comprised of two or more lipid bilayers (i.e., multilamellar). While the interior of a liposome may consist of a variety of compounds, the exterior of the liposome is accessible to the aqueous formulation comprising the liposome.
  • a liposome can be
  • the siRNA will be encapsulated by the liposome so that the siRNA is inaccessible to the aqueous medium.
  • the liposome will have a solid core; such liposomes encapsulating siRNA and having a solid core are termed "lipid nanoparticles" herein.
  • the siRNA will not be encapsulated by the liposome.
  • the siRNA can be complexed on the outer surface of the liposome by mixing preformed liposomes with RNA in an aqueous solution. In these
  • the siRNA is accessible to the aqueous medium.
  • Liposomes having siRNA bound only on their outer surface are termed "lipoplexes" herein.
  • the formulations of the description can also include PEG-conjugated lipids.
  • PEG-conjugated lipids within the scope of the description are known in the art per se.
  • Suitable PEG-lipids include PEG-phospholipids and PEG-ceramides such as, for example, PEG2000- DSPE, PEG2000-DPPE, PEG2000-DMPE, PEG2000-DOPE, PEG1000-DSPE, PEG1000- DPPE, PEG1000-DMPE, PEG1000-DOPE, PEG550-DSPE, PEG550-DPPE, PEG-550DMPE, PEG-1000DOPE, PEG-BML, PEG-Cholesterol.
  • compositions of the description can include one or more phospholipids such as, for example, l,2-distearoyl-sn-glycero-3-phosphocholine (“DSPC”), dipalmitoylphosphatidylcholine (“DPPC”), 1 ,2-dipalmitoyl-sn-glycero-3 -phosphoethanolamine (“DPPE”), and l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (“DOPE”).
  • the helper lipid is DOPE.
  • compositions that include any of the aforementioned compositions in addition to a pharmaceutically acceptable carrier or diluent.
  • Pharmaceutical formulations of the description will include at least one therapeutic agent.
  • the therapeutic agent is an siRNA.
  • siRNA may include: Sense (5'->3') GGACAGGCCUCUACAACUATT (SEQ. ID. NO. 1) Antisense (3'->5') TTCCUGUCCGGAGAUGUUGAU (SEQ. ID. NO. 2)
  • the siRNA is encapsulated by the liposome.
  • the siRNA can be outside of the liposome.
  • the siRNA can be complexed to the outside of the liposome.
  • kits for delivering a therapeutic agent to a patient comprise providing a pharmaceutical formulation including any of the foregoing compositions and a pharmaceutically acceptable carrier or diluent; and administering the pharmaceutical formulation to the patient.
  • the present disclosure relates to a pharmaceutical formulation comprising one or more physiologically acceptable surface active agents, pharmaceutical carriers, diluents, excipients, and suspension agents, or a combination thereof; and a formulation (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) disclosed herein.
  • a formulation e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent
  • Acceptable additional pharmaceutical carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety.
  • Preservatives may be provided in the pharmaceutical formulation.
  • sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives.
  • antioxidants and suspending agents may be used.
  • alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium metasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents.
  • compositions described herein can be administered to a human patient per se, or in pharmaceutical formulations where they are mixed with other active ingredients, as in combination therapy, or suitable pharmaceutical carriers or excipient(s).
  • Suitable routes of administration may include, for example, parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
  • the formulation e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent
  • the route of administration may be local or systemic.
  • the pharmaceutical formulations may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes.
  • compositions may be formulated in any conventional manner using one or more physiologically acceptable pharmaceutical carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, pharmaceutical carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
  • injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like.
  • the injectable pharmaceutical formulations may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like.
  • Physiologically compatible buffers include, but are not limited to, Hanks's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations may be utilized.
  • compositions for parenteral administration include aqueous solutions of the active formulation (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) in water-soluble form.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the formulations may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the formulations may also be formulated as a depot preparation. Such long acting formulations may be administered by intramuscular injection.
  • the formulations e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent
  • the formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions and formulations of the description may also be formulated for topical delivery and may be applied to the subject's skin using any suitable process for application of topical delivery vehicle.
  • the formulation may be applied manually, using an applicator, or by a process that involves both.
  • the formulation may be worked into the subject's skin, e.g., by rubbing.
  • Application may be performed multiple times daily or on a once-daily basis.
  • the formulation may be applied to a subject's skin once a day, twice a day, or multiple times a day, or may be applied once every two days, once every three days, or about once every week, once every two weeks, or once every several weeks.
  • Some embodiments herein are directed to a method of delivering a therapeutic agent to a cell.
  • some embodiments are directed to a method of delivering a therapeutic agent such as siRNA into a cell.
  • Suitable cells for use according to the methods described herein include prokaryotes, yeast, or higher eukaryotic cells, including plant and animal cells (e.g., mammalian cells).
  • the cells can be human fibrosarcoma cells (e.g., HT1080 cell line).
  • the cells can be hepatic stellate cells (LX2 cell line).
  • the cells can be cancer cells.
  • the cells can be stem cells (pHSC cell line).
  • Cell lines which are model systems for cancer may be used, including but not limited to breast cancer (MCF-7, MDA-MB-438 cell lines), U87 glioblastoma cell line, B 16F0 cells (melanoma), HeLa cells (cervical cancer), A549 cells (lung cancer), and rat tumor cell lines GH3 and 9L.
  • the formulations described herein can be used to transfect a cell. These embodiments may include contacting the cell with a formulation described herein that includes a therapeutic agent, to thereby deliver a therapeutic agent to the cell.
  • Conditions characterized by abnormal fibrosis may include cancer and/or a fibrotic disease.
  • Types of cancer that may be treated or ameliorated by a formulation described herein include, but are not limited to, lung cancer, pancreatic cancer, breast cancer, liver cancer, stomach cancer, and colon cancer.
  • the cancer that may be treated or ameliorated is pancreatic cancer.
  • the cancer that may be treated or ameliorated is lung cancer.
  • Types of fibrotic disease that may be treated or ameliorated by a formulation described herein include, but are not limited to, hepatic fibrosis, hepatic cirrhosis, pancreatitis, pancreatic fibrosis, cystic fibrosis, vocal cord scarring, vocal cord mucosal fibrosis, laryngeal fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis,
  • the condition that may be treated or ameliorated is hepatic fibrosis.
  • compositions or pharmaceutical compositions described herein may be administered to the subject by any suitable means.
  • methods of administration include, among others, (a) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (b) administration locally such as by injection directly in the renal or cardiac area, e.g., by depot implantation; as well as as deemed appropriate by those of skill in the art for bringing the active compound into contact with living tissue.
  • compositions suitable for administration include formulations
  • a therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed.
  • the determination of effective dosage levels can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
  • dosages may range broadly, depending upon the desired effects and the therapeutic indication. Typically, dosages may be about 10 microgram/kg to about 100 mg/kg body weight, preferably about 100 microgram/kg to about 10 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
  • compositions can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1).
  • the dose range of the composition administered to the patient can be from about 0.5 to about 1000 mg/kg of the patient's body weight.
  • the dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient.
  • the dosages will be about the same, or dosages that are about 0.1% to about 500%, more preferably about 25% to about 250% of the established human dosage.
  • a suitable human dosage can be inferred from ED50 or ID50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
  • the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
  • the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
  • the daily dosage regimen for an adult human patient may be, for example, a dose of about 0.1 mg to 2000 mg of each active ingredient, preferably about 1 mg to about 500 mg, e.g. 5 to 200 mg.
  • an intravenous, subcutaneous, or intramuscular dose of each active ingredient of about 0.01 mg to about 100 mg, preferably about 0.1 mg to about 60 mg, e.g. about 1 to about 40 mg is used.
  • dosages may be calculated as the free base.
  • the formulation is administered 1 to 4 times per day.
  • the formulations may be administered by continuous intravenous infusion, preferably at a dose of each active ingredient up to about 1000 mg per day.
  • each active ingredient up to about 1000 mg per day.
  • the formulations will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC).
  • MEC minimal effective concentration
  • the MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
  • Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10- 90% of the time, preferably between 30-90% and most preferably between 50-90%.
  • the effective local concentration of the drug may not be related to plasma concentration.
  • the amount of formulation administered may be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • Formulations disclosed herein can be evaluated for efficacy and toxicity using known methods.
  • the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
  • the toxicity of particular compounds in an animal model such as mice, rats, rabbits, or monkeys, may be determined using known methods.
  • the efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials.
  • the formulations may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a
  • compositions comprising a compound formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • each center may independently be of R-configuration or S-configuration or a mixture thereof.
  • the compounds provided herein may be enantiomerically pure or be stereoisomeric mixtures.
  • each double bond may independently be E or Z a mixture thereof.
  • all tautomeric forms are also intended to be included.
  • Step 1 Preparation of Intermediate 1: 3,3 '-azanediylbis(propan-l-ol)
  • Step 3 Preparation of Intermediate 3: ((tert-butoxycarbonyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate [0093] tert-butyl bis(3-hydroxypropyl)carbamate (4.00 g, 17.3 mmol), Et3N (4.8 mL, 34.6 mmol) and DMAP (529 mg, 4.33 mmol) were dissolved in chloroform (50 mL). While being stirred in an ice-bath, a solution of myristoyl chloride was added over 15 min. The addition was carried out in such a way that the temperature of the reaction did not exceed 30°C. The reaction was allowed to stir at room temperature overnight.
  • Step 4 Preparation of Intermediate 4: azanediylbis(propane-3,l-diyl) ditetradecanoate TFA salt
  • Step 5 Preparation ofi-Pr-DC: ((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate
  • Azanediylbis(propane-3,l-diyl) ditetradecanoate TFA salt (750 mg, 1.35 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of N,N-dimethylglycine (154 mg, 1.49 mmol), HATU (616 mg, 1.62 mmol) and DIEA (495 uL, 2.84 mmol) in DCM (5 mL). Flask was flushed with argon and allowed to stir at room temperature overnight. The reaction mixture was concentrated.
  • Step 2 Prep : tert-butyl bis(3-hydroxypropyl)carbamate '
  • Step 3 Preparation of Intermediate 3: (Z)-((tert-butoxycarbonyl)azanediyl)bis(propane-3,l- diyl) dioleate [0099] tert-butyl bis(3-hydroxypropyl)carbamate, triethylamine and DMAP were dissolved in chloroform. While being stirred in an ice-bath, a solution of oleyl chloride was added over 15 minutes. The addition was carried out in such a way that the temperature of the reaction did not exceed 30°C. The reaction was allowed to stir at room temperature overnight. Next day, MeOH (50 mL) and 0.9% saline solution (50mL) was added to quench the reaction.
  • MeOH 50 mL
  • 0.9% saline solution 50mL
  • Step 5 Preparation of i-Pr-DODC: (Z)-((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l-
  • Step 1 Preparation of Intermediate 1: ((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate
  • N-Boc diethanolamine (MW 205.25; 8.4 g, 0.041 mole), triethylamine (MW 101.19; 11.5 ml, 0.083 mol) and 4-(dimethylamino)pyridine (MW 122.17; 1.3 g, 0.01 1 mole) were dissolved in chloroform (170 mL). While being stirred in an ice/water bath, a solution of myristoyl chloride (MW 246.82; 22 mL, 80.9 mmol) in 100 mL of chloroform was added dropwise. The reaction mixture was then taken out of the cold bath, and the stirring was continued at room temperature for 2 h.
  • Step 2 Preparation of Intermediate 2: azanediylbis(ethane-2,l-diyl) ditetradecanoate TFA salt
  • Azanediylbis(ethane-2, l-diyl) ditetradecanoate TFA salt(10g, 16 mmol) was diluted with dimethylglycine (42.5g, 25 mmol), DCC (4.7 g, 23 mmol) and DIEA (6.33 mL, 40 mmol) in Pyridine (20 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was heated at 55°C overnight. Next day, the reaction mixture was concentrated.
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1.50 g, 2.85 mmol) was diluted with DCM (10 mL) and added to a pre-activated mixture of 3-(dimethylamino)propionic acid HCl salt (482 mg, 3.14 mmol), HATU (1.30 g, 3.42 mmol) and DIEA (1.04 mL, 5.98 mmol) in DCM (10 mL).
  • the round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight.
  • the reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 niL) and 10% K 2 C0 3 (20 niL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO rnL).
  • Step 1 Preparation of Intermediate 1: (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-
  • N-Boc diethanolamine (17.8 g, 0.087 mole), triethylamine (24.4 mL, 0.176 mole) and 4- (dimethylamino)pyridine (2.76 g, 0.023 mole) were dissolved in 350 ml of chloroform. While being stirred, a solution of oleyl chloride (61.6 g, 0.174 mole) in 100 ml of chloroform was added over 10 min (Alternatively, the chloroform solution of N-Boc
  • Step 3 Preparation ofi-Et-DODC: (Z)-((3-(dimethylamino)propanoyl)azanediyl)bis(ethane- 2, -diyl) dioleate
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1.00 g, 1.90 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of 4-(Dimethylamino) butyric acid HCl salt (382 mg, 2.28mmol), HATU (867 mg, 2.28 mmol) and DIEA (728 uL, 4.18 mmol) in DCM (5 mL).
  • the round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight.
  • the reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 mL) and 10% K 2 C0 3 (20 mL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO mL).
  • the round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight.
  • the reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 mL) and 10% K 2 C0 3 (20 mL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO mL).
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described.
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (730 mg, 1.14 mmol) was stirred in DCM (20 mL) with 10% K 2 C0 3 (10 mL) at 0-5 °C. After 30 min, the organic phase was separated and the aqueous phase was further extracted with DCM (10 mL). The combined organic phases are stirred with MgS0 4 for a period of 30 minutes at 0-5°C, filtered and washed with DCM (10 mL).
  • Trichloromethyl chloroformate (aka diphosgene) (257 uL, 2.13 mmol) was added to a solution of 2-(dimethylamino)ethanethiol HC1 salt (302 mg, 2.13 mmol) in dry DCM (20 mL) and stirred under a blanket of argon at room temperature for 4 h. Afterwards, DCM and excess diphosgene were removed in vacuo. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate free base (1068 mg, 2.03 mmol), DCM (20 mL) and triethylamine (580 uL, 4.16 mmol) were then added.
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described.
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1500mg, 2.34mmol) was dissolved in DCM (20mL) and placed in an ice-bath.
  • Bromoacetyl bromide (214uL, 2.46mmol) was added followed by triethylamine(685uL, 4.91 mmol).
  • the ice-bath was removed and the reaction was allowed to stir overnight at room temperature under a blanket of inert gas. Next day, diluted with DCM to lOOmL.
  • Step 2 Preparation of O104: ((2-(2-(dimethylamino)ethoxy)acetyl)azanediyl)bis(ethane-2,l-
  • Step 1 Preparation of Intermediate 1: ((2-(benzyloxy)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecan oate
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt was stirred in DCM (25 mL) with 10% K2CO 3 (12.5 mL) at 0-5°C. After 30 min, the organic layer was isolated and the aqueous layer was further extracted with DCM (12 mL). The combined organic phases are stirred with MgS0 4 for 30 min at 0-5°C, filtered, washed with DCM (12 mL).
  • Step 2 Preparation of Intermediate 2: ((2-hydroxyacetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described.
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1004 mg, 1.57 mmol) was stirred in DCM (20 mL) with 10% K 2 C0 3 (20mL) at 0-5°C. After 30 min, the organic phase was isolated and the aqueous phase was further extracted with DCM (10 mL). The combined organics are dried with MgS0 4 for 30 min at 0-5°C, filtered and washed with DCM (10 mL).
  • Step 1 Preparation of Intermediate 1: (((4-nitrophenoxy)carbonyl)azanediyl)bis(ethane-2,l- diyl) ditetradeca-noate
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt was dissolved in dry DCM (10 mL) and triethylamine (654 uL, 4.69 mmol) was added. The reaction vessel was flushed with inert gas and 4-nitrophenyl chloroformate was added. Material was allowed to stir at RT overnight. The reaction mixture was quenched with water (50 mL) and DCM (50 mL). The organic layer was isolated, and the aqueous layer was extracted further with DCM (2 x 50 mL).
  • Step 2 Preparation of CA104: (((2-(dimethylamino)ethoxy)carbonyl)azanediyl)bis(ethane- -diyl) ditetra-decanoate
  • Step 1 Preparation of intermediate 1: 2-((2-(dimethylamino)ethyl)thio) acetic acid hydrochloride:
  • Ethanol 500 mL was degassed by three times evacuation to 60 mBar for 1-2 minutes and repressurizing with nitrogen. Chloroacetic acid (36.9 g, 0.391 mol) was added and a clear solution was formed after having stirred for 5 minutes at 17-20°C. 2-(Dimethylamino)- ethanethiol hydrochloride (52.7 g, 0.372 mol) was added, and a clear solution was formed after having stirred for 20 minutes at 25°C. Solid sodium hydroxide (47.7 g, 1.19 mol) was added in portions over a period of 20 minutes with cooling in order to keep the temperature below 35°C - a short period at 44°C was observed.
  • the aqueous phase was washed with DCM (3x 100 mL) to remove the disulphide impurity (all 3 washes required). Concentrated HCl was added to the aqueous phase (pH 10.7, temp. 22°C) until the pH was 1.4 (57.5 mL added, temp. 35°C). The aqueous phase was washed with DCM (100 mL) and then concentrated to dryness (bath temperature 55°C). Toluene (250 mL) was added, the mixture was concentrated to dryness (bath temperature 55°C) and this was repeated once to give a wet white solid (98 g).
  • Acetonitrile (750 niL) was added to the solid, the mixture was stirred at 55°C for a period of 45 minutes, and then filtered through a G3 glass-sintered plate.
  • Acetonitrile (250 mL) was added to the filter cake, the mixture was stirred at 55°C for a period of 25 minutes and then filtered through a G3 glass-sintered plate, washing with acetonitrile (50 mL).
  • the combined filtrates are concentrated to 300 mL, resulting in a heavy, white precipitate.
  • the mixture was cooled under nitrogen and stirred at 0°C for a period of 30 minutes.
  • Step 2 Preparation ofS104: ((2-((2-(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane- -diyl) ditetradecanoate
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (152 g, 238 mmol) was stirred with DCM (2.3 L) and 10% potassium bicarbonate (1.15 L) at 0-5°C. The organic phase was separated and the aqueous phase was further extracted with DCM (1.15 L). The combined organic phases were stirred with magnesium sulfate hydrate (236 g) for a period of 30 minutes at
  • Tripotassium phosphate (85 g, 0.40 mol) and dipotassium hydrogen phosphate (226 g, 1.30 mol) were added to purified water (1.7 L), and the solution formed with pH 10.9 was cooled to 18-20°C.
  • DCM (1.3 L) and recrystallized S104 hydrochloride (133.0 g, 0.188 mol) are added, and the mixture was stirred for a period of 10 min minutes. A clear organic phase was separated at moderate rate (over a period of 35 minutes), and the turbid aqueous phase was further extracted with DCM (650 mL).
  • Step 1 Preparation of Intermediate 1: (9Z,9'Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane- -diyl) bis( tetradec-9-enoate)
  • N-Boc-diethanolamine (454 mg, 2.21 mmol), myristoleic acid (1000 mg, 4.42 mmol) and DMAP (54 mg, 0.442 mmol) was dissolved in DCM (25 mL) and placed in a water bath at ambient temperature in a round-bottom flask was flushed with inert gas.
  • EDC HC1 salt (932 mg, 4.86 mmol) was added in 3 portions over 5 min. The reaction was allowed to stir overnight at room temperature under a blanket of inert gas. Next day, added FLO (25 mL) and stirred for 10 min. The organic layer was isolated and the aqueous layer was further extracted with DCM (50 mL).
  • Step 2 Preparation of Intermediate 2: (9Z,9'Z)-azanediylbis(ethane-2,l-diyl) bis(tetradec-9- enoate
  • the turbid aqueous phase was extracted with DCM (2 x 20 rnL).
  • the combined organic extracts are dried with MgS0 4 , filtered and concentrated.
  • Step 1 Preparation of Pro-DC: (R)-((l-methylpyrrolidine-2-carbonyl)azanediyl)bis(ethane-
  • Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt 1000 mg, 1.56 mmol
  • DCM 10 mL
  • N-Methyl-L-Proline 228 mg, 1.77 mmol
  • HOBtH 2 0 239 mg, 1.77 mmol
  • NMM 365 uL, 3.32 mmol
  • N-Boc-diethanolamine (5 g, 24.4 mmol), linoleic acid (14.4 g, 51.2 mmol) and was dissolved in DCM (100 mL).
  • EDC HC1 salt (10.3 g, 53.7 mmol) was added followed by DMAP (596 mg, 4.88 mmol).
  • the reaction was allowed to stir for about 12 hours at room temperature under a blanket of inert gas. Thereafter, 50 mL of water and 50 mL of methanol were added, and the mixture was stirred for 10 min. The organic layer was isolated and the aqueous layer was further extracted with DCM (150 mL). The combined organics were dried (MgS0 4 ) for 10 min, filtered and concentrated.
  • Step 2 Preparation of Intermediate 2: (9Z,9'Z,12Z,12'Z)-azanediylbis(ethane-2,l-diyl)
  • Step 1 Preparation of TU104-Dlin: (9Z,9'Z,12Z,12'Z)-((2-((2- azanediyl)bis(ethan [0160] Synthesis of (9Z,9'Z,12Z, 12'Z)-azanediylbis(ethane-2,l-diyl) bis(octadeca-9, 12- dienoate) previously described.
  • Trichloromethyl chloroformate (aka diphosgene) (740 uL, ) was added to a solution (9Z,9'Z, 12Z, 12'Z)-azanediylbis(ethane-2,l-diyl) bis(octadeca-9, 12-dienoate) (2.6 g) in dry DCM (40 mL) and stirred under a blanket of argon at room temperature for 12 hourrs. DCM and excess diphosgene were removed in vacuo. 2-(dimethylamino)ethane thiol HC1 salt (2.9 g), DCM (40 mL) and triethylamine (3.7 mL) were then added.
  • Non-diVA siRNA containing liposomes lonizable lipid, DOPE, cholesterol, and a PEG-conjugated lipid were solubilized in absolute EtOH (200 proof) at a final weight concentration of ⁇ 4.4 mg/mL.
  • the siRNA was solubilized in citrate buffer at a concentration -0.26 mg/mL and the temperature was adjusted to 35-40°C.
  • the ethanol/lipid mixture was then added to the siRNA-containing buffer while stirring to spontaneously form siRNA loaded liposomes. Lipids were combined with siRNA to reach a final total lipid to siRNA ratio of 7: 1 to 14: 1 (w wt).
  • the siRNA loaded liposomes were diafiltered against lOx volumes of PBS to remove ethanol and exchange the buffer. Final product was filtered through 0.22 ⁇ , sterilizing grade, filter for bioburden reduction. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI ⁇ 0.2, and >85% RNA encapsulation (entrapment) efficiency.
  • siRNA containing liposomes co-solubilized with diVA ⁇ siRNA- diVA-Liposome formulations were prepared using the method described above.
  • diVA-PEG- diVA was co-solubilized in absolute ethanol with the other lipids (ionizable lipid, DOPE, cholesterol, and PEG-conjugated lipids) prior to addition to the siRNA containing buffer.
  • Molar content of diVA-PEG-diVA ranged from 0.1 to 5 mol%. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI ⁇ 0.2, and >85% entrapment efficiency.
  • siRNA-diVA-Liposome formulations and siRNA-Liposome formulations were prepared using the method described above.
  • Cationic lipid was co-solubilized in absolute ethanol with the other lipids (ionizable lipid, DOPE, cholesterol, PEG-conjugated lipids, and diVA-PEG-diVA) prior to addition to the siRNA containing buffer.
  • Molar content of cationic lipid ranged from 5 to 40 mol%. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI ⁇ 0.2, and >85% entrapment efficiency.
  • DMNQ short-term liver damage model
  • a hepatotoxic agent such as dimethylnitrosamine (DMN)
  • DMN dimethylnitrosamine
  • liver lobes were excised and both gp46 and MRPL19 mRNA levels were determined by quantitative RT-PCR (TaqMan) assay. mRNA levels for gp46 were normalized to MRPL19 levels. Results are depicted in Figure 4.
  • Several combinations of ionizable:cationic lipids achieved 50% reduction in gene expression expression for a single, 0.5 mg per kg of animal body weight, dose of encapsulated siRNA.
  • in vitro toxicology data in vitro cytotoxicity (HepG2 @ 200 nM)
  • HepG2 cells an adherent cell line derived from human hepatocellular carcinoma, was cultured in MEM/EBSS (Hyclone, Logan, Utah, Cat# SH30024.01)
  • Chemiluminescent signal were measured on Clarity Luminescence Microplate Reader (502- Biotek, Winooski, Vermont). Viability was calculated based on % of chemiluminescent signal in formulation treated well normalized against mock treated wells.
  • HEDC:S104 (20:20) formulation of the present description is exceptionally well tolerated as shown in toxicity studies. No toxicity was observed when the formulation was injected intravenously in rats and monkey at doses up to 25 mg/kg and 12 mg/kg, respectively, which is considered by those skilled in the art to be superior.
  • Transfection method is same for LX-2 and pHSCs.
  • the liposome formulations or lipoplex formulations of the description were mixed with growth medium at desired concentrations. 100 ⁇ of the mixture was added to the cells in 96-well plate and cells were incubated for 30 min at 37 °C in the incubator with 5% C0 2 . After 30 min, medium was replaced with fresh growth medium. After 48 h of transfection, cells were processed using Cell-to-Ct lysis reagents (Applied Biosystems) according to the manufacturer's instructions. Quantitatve (q) RT-PCR for measuring HSP47 mRNA expression
  • HSP47 and GAPDH TaqMan® ® assays and One-Step RT-PCR master mix were purchased from Applied Biosystems. Each PCR reaction contained the following composition: One-step RT-PCR mix 5 ⁇ , TaqMan® RT enzyme mix 0.25 ⁇ , TaqMan® gene expression assay probe (HSP47) 0.25 ⁇ , TaqMan® gene expression assay probe (GAPDH) 0.5 ⁇ , RNase free water 3.25 ⁇ , Cell lysate 0.75 ⁇ , Total volume of 10 ⁇ . GAPDH was used as endogenous control for the relative quantification of HSP47 mRNA levels. Quantitative RT-PCR was performed in ViiA 7 realtime PCR system (Applied Biosciences). All values were normalized to the average HSP47 expression of the mock transfected cells and expressed as percentage of HSP47 expression compared to mock.

Abstract

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Description

LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of United States Provisional Patent Application No.: 61/657,480 filed June 8, 2012, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
[0002] The description is directed to ionizable lipids for enhancing the delivery of therapeutic agents.
BACKGROUND
[0003] A number of techniques are available for delivering a therapeutic agent, for example, siRNA, nucleic acids, etc., into a cell. These techniques include viral and non-viral transfection systems. Non-viral transfection systems can include, for example, polymers, lipids, liposomes, micelles, dendrimers, and nanomaterials. Polymers that have been studies for cell transfection include cationic polymers such as, for example, poly(L-lysine) ("PLL"), polyethyleneimine ("PEI"), chitosan, and poly(2-dimethylamino)ethyl methacrylate
("pDMAEMA").
[0004] The viral and non- viral transfection techniques have drawbacks, however. For example, viral systems can yield high transfection efficiency, but may not be entirely safe. In addition, viral systems can be complicated and/or expensive to prepare.
[0005] Non-viral transfection systems, for example, those employing cationic polymers, have been reported to transfer plasmid DNA into cells. Cationic polymers, however, can be unstable and can be toxic to cells.
[0006] As such, there is a need for new compounds, compositions, and methods for using cationic composition to improve the delivery of therapeutic agents to cells, tissues, and organisms.
SUMMARY
[0007] The present description is directed to ionizable lipid compounds of formula I
Figure imgf000004_0001
wherein n and m are independently 1, 2, 3, or 4; Ri and R2 are independently
Cio-18 alkyl or C12-1 8 alkenyl; X is -CH2-, S, O, N, or absent; L is C1-4 alkylene; -S-C1-4 alkylene; -
O-Ci-4 alkylene; -0-C(0)-C1-4 alkylene; -S(0)2-Ci-4 alkylene;
Figure imgf000004_0002
or a pharmaceutically acceptable salt form thereof. Compositions, pharmaceutical formulations, drug carriers, and methods of using the compounds of formula I are also described.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] FIG. 1 depicts in vitro synergistic efficacy of ionizable lipid:ionizable lipid embodiments of the present description
[0009] FIG. 2 depicts in vitro synergistic efficacy of ionizable lipid:ionizable lipid embodiments of the present description
[0010] FIG. 3 depicts in vitro synergistic efficacy of ionizable lipid: cationic lipid embodiments of the present description
[0011] FIG. 4 depicts in vivo efficacy of ionizable lipid: cationic lipid embodiments of the present description
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0012] The present description is directed to ionizable lipid compounds, as well as their uses in delivering therapeutic agents to cells, tissues, and organisms.
[0013] Within the scope of the description are ionizable lipid compounds of formula I:
Figure imgf000005_0001
wherein
n and m are independently 1, 2, 3, or 4;
Ri and R2 are independently Cio-is alkyl or C12-18 alkenyl;
X is -CH2-, S, O, N, or absent;
L is Ci-4 alkylene; -S-C1-4 alkylene; -0-C1-4 alkylene; -0-C(0)-Ci
S(0)2-Ci_4 alkylene;
Figure imgf000005_0002
or a pharmaceutically acceptable salt form thereof.
[0014] Within the scope of the description, n and m can be the same or different. In preferred embodiments, n and m are the same. Particularly preferred are those embodiments wherein n and m are both 1 or n and m are both 2.
[0015] In some embodiments of the description, X is a bond. In other embodiments, X is -CH2-. In still others, X is S. Also preferred, are embodiments wherein X is O. Embodiments wherein X is N are also within the scope of the description.
[0016] In some embodiments of the description, L is C1-4 alkylene. In other
embodiments, L is
-S-Ci-4 alkylene. In yet other embodiments, L is -O-C1-4 alkylene. In still other embodiments, L is
-0-C(0)-Ci_4 alkylene. Alternatively, L is -S(0)2-C1-4 alkylene. Also within the scope of the description are embodiments wherein L is
Figure imgf000005_0003
[0017] In those embodiments wherein X is a bond, L is preferably C1-4 alkylene. Such examples of L include -CH2-, -CH2-CH2-, -CH2 CH2CH2-, and -CH2 CH2CH2CH2-. In other embodiments wherein X is a bond, L is S C-|_4alkylene^ ^ example, S CH2 [0018] In those embodiments wherein X is -CH2-, L is preferably -S-C1-4 alkylene. Such examples of L include -S-CH2-, -S-CH2-CH2-, -S-CH2 CH2CH2-, and -S-CH2
CH2CH2CH2-.
[0019] In other embodiments wherein X is -CH2-, L is preferably -S(0)2-C1-4 alkylene. Such examples of L include -S(0)2-CH2, -S(0)2-CH2-CH2, -S(0)2-CH2-CH2-CH2-, and S(0)2-CH2-CH2-CH2-CH2-.
[0020] In yet other embodiments wherein X is -CH2-, L is -0-C1-4 alkylene. Such examples of L include -0-CH2-, -0-CH2-CH2-, -0-CH2 CH2CH2-, and -0-CH2 CH2CH2CH2-.
[0021] In those embodiments of the description wherein X is S, L is preferably Ci_ 4alkylene. Such examples of L include -CH2-, -CH2-CH2-, -CH2 CH2CH2-, and -CH2
CH2CH2CH2-.
[0022] In those embodiments wherein X is O, L is preferably C1-4 alkylene. Such examples of L include -CH2-, -CH2-CH2-, -CH2 CH2CH2-, and -CH2 CH2CH2CH2-.
[0023] Within the scope of the description, Ri and R2 can be the same or different. Preferably, Ri and R2 are the same. Preferably, Ri and R2 are Cw-is alkyl. Also preferred are embodiments wherein the Cio-is alkyl is a straight-chain C10-i8 alkyl. More preferred are embodiments wherein Ri and R2 are C12-18 alkyl. Also preferred are embodiments wherein Ri and R2 are
C12- 15 alkyl. In most preferred embodiments, Ri and R2 are both C13 alkyl.
[0024] In other embodiments of the description, Ri and R2 are C12-18 alkenyl.
Preferably, Ri and R2 are and R2 are each oleyl:
Figure imgf000006_0001
[0025] In other embodiments of the description, Ri and R2 are C12-18 alkenyl.
Preferably, Ri and R2 are C13- linoleoyl.
Figure imgf000006_0002
[0026] Also within the scope of the description are compositions comprising a compound of formula I in a liposome, wherein the liposome comprises a bilayer of lipid molecules. While the compound of formula I can comprise any mole percentage of the lipid molecules in such compositions, it is preferred that the compound of formula I is about 5 to about 50 mol % of the lipid molecules of the compositions of the description.
[0027] Compositions of the description comprising a compound of formula I in a liposome can contain more than one compound of formula I. In preferred embodiments, such compositions of the description include two compounds of formula I. In those embodiments, it is preferred that the molar ratio of the two compounds of formula I is about 10:30 to about 30: 10.
[0028] Compositions of the description comprising a compound of formula I in a liposome may further comprise a cationic lipid. In such embodiments, the cationic lipid is about 5 to about 40 mol % of the lipid molecules of the composition. Also in these embodiments comprising a compound of formula I in a liposome with a cationic lipid, the molar ratio of the compound of formula I to the cationic lipid is about 5:35 to about 35:5. More preferable, the ratio is about 10:30 to about 30: 10.
[0029] Within the scope of the description, any compositions of the description may further comprise a liquid medium. Preferably, the liquid medium is suitable for injection into a living organism. In some embodiments, the liquid medium comprises an organic solvent.
Alternatively, the liquid medium used in certain embodiments of the description comprises water and an organic solvent. In other embodiments of the description, the liquid medium may further comprise a non-aqueous medium.
[0030] Also within the scope of the description, any compositions of the description may further comprise at least one phospholipid.
[0031] In other embodiments of the description, any compositions of the description may further comprise at least one PEG-conjugated lipid.
[0032] Also within the scope of the description are stellate-cell-specific drug carriers. These embodiments of the description include any of the aforementioned compositions, as well as a stellate cell specific amount of a targeting molecule consisting of a (retinoid)n-linker- (retinoid)n, wherein n=0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule.
[0033] In preferred embodiments, the drug carriers of the description will further comprising a siRNA molecule.
[0034] Also within the scope of the description are pharmaceutical formulations.
Pharmaceutical formulations within the scope of the description include any of the
aforementioned drug carrier of the description and a pharmaceutically acceptable carrier or diluent. In is preferred that in such formulations, the siRNA is encapsulated by the liposome of the compositions of the description.
[0035] Also within the scope of the description are methods of delivering a drug to a patient in need of treatment. These methods comprise providing a pharmaceutical formulation within the scope of the description and administering the pharmaceutical formulation to the patient. Definitions
[0036] The following terms are used throughout this specification.
[0037] As used herein, "cationic lipid" refers to a compound that includes at least one lipid moiety and a positively charged quaternary nitrogen associated with a counterion. "Lipids" are understood in the art to be comprises of a hydrophobic alkyl or alkenyl moiety and a carboxylic acid or ester moiety. Preferred cationic lipids for use in the present description include:
Figure imgf000008_0001
("HEDODC").
[0038] As used herein, "ionizable lipid" refers to a compound of formula I within the scope of the description. These compounds are capable of forming charged species when contacted with an appropriate counterion species, for example, a species that includes an ionizable hydrogen atom.
[0039] As used herein, "alkyl" refers to a straight or branched fully saturated (no double or triple bonds) hydrocarbon group, for example, a group having the general formula - CnH2n+1. The alkyl group may have 1 to 50 carbon atoms (whenever it appears herein, a numerical range such as "1 to 50" refers to each integer in the given range; e.g., "1 to 50 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 50 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 30 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 5 carbon atoms. The alkyl group of the compounds may be designated as "C1-4 alkyl" or similar designations. By way of example only, "C1-4 alkyl" indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec -butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like.
[0040] As used herein, "alkylene" refers to an alkanediyl functional group, for example, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and the like.
[0041] As used herein, "alkenyl" refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds. An alkenyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution unless otherwise indicated. Oleyl is an example of such an alkenyl group.
[0042] As used herein, the term "pharmaceutical carrier" refers to a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example dimethyl sulfoxide (DMSO) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism
[0043] As used herein, the term "diluent" refers to chemical compounds diluted in water that will dissolve the formulation of interest (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) as well as stabilize the biologically active form of the formulation. Salts dissolved in buffered solutions are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of the formulation. As used herein, an "excipient" refers to an inert substance that is added to a formulation to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability, etc., to the composition. A "diluent" is a type of excipient.
[0044] "Organic solvents" used within the scope of the description are known in the art, per se. and include, for example,
Figure imgf000009_0001
alcohols, dimethyl sulfoxide ("DMSO"), and the like.
[0045] As used herein, "therapeutic agent" refers to a compound that, upon
administration to a mammal in a therapeutically effective amount, provides a therapeutic benefit to the mammal. A therapeutic agent may be referred to herein as a drug. Those skilled in the art will appreciate that the term "therapeutic agent" is not limited to drugs that have received regulatory approval. A "therapeutic agent" can be operatively associated with a compound as described herein, a retinoid, and/or a second lipid. For example, a second lipid as described herein can form a liposome, and the therapeutic agent can be operatively associated with the liposome, e.g., as described herein.
[0046] As used herein, a "retinoid" is a member of the class of compounds consisting of four isoprenoid units joined in a head-to-tail manner, see G. P. Moss, "Biochemical
Nomenclature and Related Documents," 2nd Ed. Portland Press, pp. 247-251 (1992). "Vitamin A" is the generic descriptor for retinoids exhibiting qualitatively the biological activity of retinol. As used herein, retinoid refers to natural and synthetic retinoids including first generation, second generation, and third generation retinoids. Examples of naturally occurring retinoids include, but are not limited to, (1) 1 1-cis-retinal, (2) all-trans retinol, (3) retinyl palmitate, (4) all- trans retinoic acid, and (5) 13-cis-retinoic acids. Furthermore, the term "retinoid" encompasses retinols, retinals, retinoic acids, retinoids, and derivatives thereof.
[0047] As used herein, "retinoid conjugate" refers to a molecule that includes at least one retinoid moiety. In preferred embodiments of the description, the retinoid conjugate will be present at a concentration of about 0.3 to about 30 weight percent, based on the total weight of the composition or formulation, which is equivalent to about 0.1 to about 10 mol.%, which is equivalent to a molar ratio of about 0.1 to about 10. Preferably, the retinoid conjugate is a retinoid-linker-lipid molecule or a retinoid-linker-retinoid molecule.
[0048] An example of a retinoid conjugates include those compounds of formula II:
Figure imgf000010_0001
II
wherein q, r, and s are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and enantiomers and diastereomers thereof.
[0049] Preferred compounds of formula II include those wherein q, r, and s are each independently 1, 2, 3, 4, 5, 6, or 7. More preferred are those compounds of formula II wherein q, r, and s are each independently 3, 4, or 5. Most preferred are those compounds of formula II wherein q is 3, r is 5, and s is 3. One example of a compound of formula II is
Figure imgf000011_0001
DiVA-PEG-DiVA
[0050] DiVA-PEG-DiVA includes stereocenters and all enantiomers and diastereomers are considered to be within the scope of the description.
[0051] As used herein, "retinoid-linker-lipid molecule" refers to a molecule that includes at least one retinoid moiety attached to at least one lipid moiety through at least one linker such as, for example, a PEG moiety.
[0052] As used herein, "retinoid linker-retinoid molecule" refers to a molecule that includes at least one retinoid moiety attached to at least one other retinoid moiety (which may be the same or different) through at least one linker such as, for example, a PEG moiety.
[0053] As used herein, the terms "lipid" and "lipophilic" are used herein in their ordinary meanings as understood by those skilled in the art. Non-limiting examples of lipids and lipophilic groups include fatty acids, sterols, C2-C50 alkyl, C2-C50 heteroalkyl, C2-C50 alkenyl, C2-C50 heteroalkenyl, C2-C50 aryl, C2-C50 heteroaryl, C2-C50 alkynyl, C2-C50 heteroalkynyl, C2-C50 carboxyalkenyl, and C2-C50 carboxyheteroalkenyl. A fatty acid is a saturated or unsaturated long-chain monocarboxylic acid that contains, for example, 12 to 24 carbon atoms A lipid is characterized as being essentially water insoluble, having a solubility in water of less than about 0.01% (weight basis). As used herein, the terms "lipid moiety" and "lipophilic moiety" refers to a lipid or portion thereof that has become attached to another group. For example, a lipid group may become attached to another compound (e.g., a monomer) by a chemical reaction between a functional group (such as a carboxylic acid group) of the lipid and an appropriate functional group of a monomer.
[0054] As used herein, "stellate cell" refers to neurons with several dendrites radiating from the cell body. Examples of stellate cells are inhibitory interneurons.
[0055] As used herein, "siRNA" refers to small interfering RNA, also known in the art as short interfering RNA or silencing RNA. siRNA is a class of double stranded RNA molecules that have a variety of effects known in the art, the most notable being the interference with the expression of specific genes and protein expression. [0056] The term "liposome" is used herein in its ordinary meaning as understood by those skilled in the art, and refers to a lipid bilayer structure that contains lipids attached to polar, hydrophilic groups which form a substantially closed structure in aqueous media. In some embodiments, the liposome can be operatively associated with one or more compounds, such as a therapeutic agent and a retinoid. A liposome may be comprised of a single lipid bilayer (i.e., unilamellar) or it may comprised of two or more lipid bilayers (i.e., multilamellar). While the interior of a liposome may consist of a variety of compounds, the exterior of the liposome is accessible to the aqueous formulation comprising the liposome. A liposome can be
approximately spherical or ellipsoidal in shape.
[0057] In some embodiments, the siRNA will be encapsulated by the liposome so that the siRNA is inaccessible to the aqueous medium. When encapsulating siRNA, the liposome will have a solid core; such liposomes encapsulating siRNA and having a solid core are termed "lipid nanoparticles" herein. In other embodiments, the siRNA will not be encapsulated by the liposome. In such embodiments, the siRNA can be complexed on the outer surface of the liposome by mixing preformed liposomes with RNA in an aqueous solution. In these
embodiments, the siRNA is accessible to the aqueous medium. Liposomes having siRNA bound only on their outer surface are termed "lipoplexes" herein.
[0058] The formulations of the description can also include PEG-conjugated lipids. PEG-conjugated lipids within the scope of the description are known in the art per se. Suitable PEG-lipids include PEG-phospholipids and PEG-ceramides such as, for example, PEG2000- DSPE, PEG2000-DPPE, PEG2000-DMPE, PEG2000-DOPE, PEG1000-DSPE, PEG1000- DPPE, PEG1000-DMPE, PEG1000-DOPE, PEG550-DSPE, PEG550-DPPE, PEG-550DMPE, PEG-1000DOPE, PEG-BML, PEG-Cholesterol. PEG2000-Ceramide, PEGIOOO-Ceramide, PEG750-Ceramide, PEG550-Ceramide.
[0059] The foregoing compositions of the description can include one or more phospholipids such as, for example, l,2-distearoyl-sn-glycero-3-phosphocholine ("DSPC"), dipalmitoylphosphatidylcholine ("DPPC"), 1 ,2-dipalmitoyl-sn-glycero-3 -phosphoethanolamine ("DPPE"), and l,2-dioleoyl-sn-glycero-3-phosphoethanolamine ("DOPE"). Preferably, the helper lipid is DOPE.
[0060] Also within the scope of the description are pharmaceutical formulations that include any of the aforementioned compositions in addition to a pharmaceutically acceptable carrier or diluent. Pharmaceutical formulations of the description will include at least one therapeutic agent. Preferably, the therapeutic agent is an siRNA. It is envisioned that any siRNA molecule can be used within the scope of the description. For example, siRNA may include: Sense (5'->3') GGACAGGCCUCUACAACUATT (SEQ. ID. NO. 1) Antisense (3'->5') TTCCUGUCCGGAGAUGUUGAU (SEQ. ID. NO. 2)
and
Sense (5'->3') GGACAGGCCUGUACAACUATT (SEQ. ID. NO. 3)
Antisense (3'->5') TTCCUGUCCGGACAUGUUGAU (SEQ. ID. NO. 4)
[0061] In preferred formulations of the description including siRNA, the siRNA is encapsulated by the liposome. In other embodiments, the siRNA can be outside of the liposome. In those embodiments, the siRNA can be complexed to the outside of the liposome.
[0062] Also within the scope of the description are methods of delivering a therapeutic agent to a patient. These methods comprise providing a pharmaceutical formulation including any of the foregoing compositions and a pharmaceutically acceptable carrier or diluent; and administering the pharmaceutical formulation to the patient.
[0063] In another aspect, the present disclosure relates to a pharmaceutical formulation comprising one or more physiologically acceptable surface active agents, pharmaceutical carriers, diluents, excipients, and suspension agents, or a combination thereof; and a formulation (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) disclosed herein. Acceptable additional pharmaceutical carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety. Preservatives, stabilizers, dyes, and the like may be provided in the pharmaceutical formulation. For example, sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used. In various embodiments, alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium metasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents.
[0064] The pharmaceutical formulations described herein can be administered to a human patient per se, or in pharmaceutical formulations where they are mixed with other active ingredients, as in combination therapy, or suitable pharmaceutical carriers or excipient(s).
Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, 18th edition, 1990.
[0065] Suitable routes of administration may include, for example, parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections. The formulation (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate. Additionally, the route of administration may be local or systemic.
[0066] The pharmaceutical formulations may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes.
[0067] Pharmaceutical formulations may be formulated in any conventional manner using one or more physiologically acceptable pharmaceutical carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, pharmaceutical carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
[0068] Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. In addition, if desired, the injectable pharmaceutical formulations may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. Physiologically compatible buffers include, but are not limited to, Hanks's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations may be utilized.
[0069] Pharmaceutical formulations for parenteral administration, e.g., by bolus injection or continuous infusion, include aqueous solutions of the active formulation (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The formulations may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0070] In addition to the preparations described previously, the formulations may also be formulated as a depot preparation. Such long acting formulations may be administered by intramuscular injection. Thus, for example, the formulations (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[0071] The compositions and formulations of the description may also be formulated for topical delivery and may be applied to the subject's skin using any suitable process for application of topical delivery vehicle. For example, the formulation may be applied manually, using an applicator, or by a process that involves both. Following application, the formulation may be worked into the subject's skin, e.g., by rubbing. Application may be performed multiple times daily or on a once-daily basis. For example, the formulation may be applied to a subject's skin once a day, twice a day, or multiple times a day, or may be applied once every two days, once every three days, or about once every week, once every two weeks, or once every several weeks.
[0072] Some embodiments herein are directed to a method of delivering a therapeutic agent to a cell. For example, some embodiments are directed to a method of delivering a therapeutic agent such as siRNA into a cell. Suitable cells for use according to the methods described herein include prokaryotes, yeast, or higher eukaryotic cells, including plant and animal cells (e.g., mammalian cells). In some embodiments, the cells can be human fibrosarcoma cells (e.g., HT1080 cell line). In other embodiments, the cells can be hepatic stellate cells (LX2 cell line). In other embodiments, the cells can be cancer cells. In yet other embodiments, the cells can be stem cells (pHSC cell line). Cell lines which are model systems for cancer may be used, including but not limited to breast cancer (MCF-7, MDA-MB-438 cell lines), U87 glioblastoma cell line, B 16F0 cells (melanoma), HeLa cells (cervical cancer), A549 cells (lung cancer), and rat tumor cell lines GH3 and 9L. In these embodiments, the formulations described herein can be used to transfect a cell. These embodiments may include contacting the cell with a formulation described herein that includes a therapeutic agent, to thereby deliver a therapeutic agent to the cell.
[0073] Disclosed herein are methods for treating a condition characterized by abnormal fibrosis, which may include administering a therapeutically effective amount of a formulation described herein. Conditions characterized by abnormal fibrosis may include cancer and/or a fibrotic disease. Types of cancer that may be treated or ameliorated by a formulation described herein include, but are not limited to, lung cancer, pancreatic cancer, breast cancer, liver cancer, stomach cancer, and colon cancer. In an embodiment, the cancer that may be treated or ameliorated is pancreatic cancer. In another embodiment, the cancer that may be treated or ameliorated is lung cancer. Types of fibrotic disease that may be treated or ameliorated by a formulation described herein include, but are not limited to, hepatic fibrosis, hepatic cirrhosis, pancreatitis, pancreatic fibrosis, cystic fibrosis, vocal cord scarring, vocal cord mucosal fibrosis, laryngeal fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis,
myelofibrosis, retroperitoneal fibrosis, and nephrogenic systemic fibrosis. In an embodiment, the condition that may be treated or ameliorated is hepatic fibrosis.
[0074] The formulations or pharmaceutical compositions described herein may be administered to the subject by any suitable means. Non-limiting examples of methods of administration include, among others, (a) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (b) administration locally such as by injection directly in the renal or cardiac area, e.g., by depot implantation; as well as as deemed appropriate by those of skill in the art for bringing the active compound into contact with living tissue.
[0075] Pharmaceutical compositions suitable for administration include formulations
(e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) where the active ingredients are contained in an amount effective to achieve its intended purpose. The therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0076] As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
[0077] In non-human animal studies, applications of potential products are commenced at higher dosage levels, with dosage being decreased until the desired effect is no longer achieved or adverse side effects disappear. The dosage may range broadly, depending upon the desired effects and the therapeutic indication. Typically, dosages may be about 10 microgram/kg to about 100 mg/kg body weight, preferably about 100 microgram/kg to about 10 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
[0078] The exact formulation, route of administration and dosage for the
pharmaceutical compositions can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1). Typically, the dose range of the composition administered to the patient can be from about 0.5 to about 1000 mg/kg of the patient's body weight. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient. In instances where human dosages for compounds have been established for at least some condition, the dosages will be about the same, or dosages that are about 0.1% to about 500%, more preferably about 25% to about 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compositions, a suitable human dosage can be inferred from ED50 or ID50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
[0079] It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
[0080] Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, a dose of about 0.1 mg to 2000 mg of each active ingredient, preferably about 1 mg to about 500 mg, e.g. 5 to 200 mg. In other embodiments, an intravenous, subcutaneous, or intramuscular dose of each active ingredient of about 0.01 mg to about 100 mg, preferably about 0.1 mg to about 60 mg, e.g. about 1 to about 40 mg is used. In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. In some embodiments, the formulation is administered 1 to 4 times per day.
Alternatively the formulations may be administered by continuous intravenous infusion, preferably at a dose of each active ingredient up to about 1000 mg per day. As will be understood by those of skill in the art, in certain situations it may be necessary to administer the formulations disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections. In some embodiments, the formulations will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
[0081] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. [0082] Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10- 90% of the time, preferably between 30-90% and most preferably between 50-90%.
[0083] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
[0084] The amount of formulation administered may be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
[0085] Formulations disclosed herein (e.g., the formulation that can include a compound, a retinoid, a second lipid, a stabilizing agent, and/or a therapeutic agent) can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials.
Recognized in vitro models exist for nearly every class of condition, including but not limited to cancer, cardiovascular disease, and various immune dysfunction. Similarly, acceptable animal models may be used to establish efficacy of chemicals to treat such conditions. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, and regime. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.
[0086] The formulations may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a
governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary
administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
[0087] It is understood that, in any compound described herein having one or more stereocenters, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure or be stereoisomeric mixtures. In addition it is understood that, in any compound having one or more double bond(s) generating geometrical isomers that can be defined as E or Z each double bond may independently be E or Z a mixture thereof. Likewise, all tautomeric forms are also intended to be included.
[0088] Preferred compounds of formula I within the scope of the description are set forth in Table 1. In vitro and in vivo data (see infra) is also set forth in Table 1.
Table 1
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
[0089] The description can be further exemplified by reference to the following examples. These examples are illustrative, only, and are not intended to limit the description. EXPERIMENTAL SECTION
[0090] Preparation of ((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate (1-Pr-DC)
Figure imgf000023_0001
Step 1: Preparation of Intermediate 1: 3,3 '-azanediylbis(propan-l-ol)
H2N'^v-/Ss-OH HO'
[0091] A mixture of 3-amino-l-propanol (14.5 mL, 19.0 mmol), l-chloro-3 -hydroxy propane (8.00 mL, 95.6 mmol) and H20 (~50mL) was refluxed over 24 hours. Potassium hydroxide (5.40 g) was then added. After dissolution, the whole of the water was evaporated to leave viscous oil and large quantities of potassium chloride. These were filtered and washed with dry acetone and dichloromethane. The organic phase was dried over Na2S04, filtered and evaporated to leave an oil. Purification by silica gel chromatography eluating with a
DCM/MeOH gradient yielded 3,3'-azanediylbis(propan-l-ol) (12.5g).
Step 2: Preparation of Intermediate 2: tert-butyl bis(3-hydroxypropyl)carbamate
HO^^^^N^^^^OH ► HO^^^N^^^^OH
H Boc
[0092] 3,3'-azanediylbis(propan-l-ol) (12.5 g, 95.4 mmol) was diluted in DCM (25 mL). A solution of di-tert-butyl dicarbonate (26.0 g, 119 mmol) in DCM (25 mL) was slowly added while stirring under a blanket of argon gas. Reaction was allowed to stir overnight. The reaction mixture was concentrated. Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded tert-butyl bis(3-hydroxypropyl)carbamate.
Step 3: Preparation of Intermediate 3: ((tert-butoxycarbonyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate
Figure imgf000023_0002
[0093] tert-butyl bis(3-hydroxypropyl)carbamate (4.00 g, 17.3 mmol), Et3N (4.8 mL, 34.6 mmol) and DMAP (529 mg, 4.33 mmol) were dissolved in chloroform (50 mL). While being stirred in an ice-bath, a solution of myristoyl chloride was added over 15 min. The addition was carried out in such a way that the temperature of the reaction did not exceed 30°C. The reaction was allowed to stir at room temperature overnight. Next day, MeOH (50 mL) and 0.9% saline solution (50 mL) was added to quench the reaction. The organic layer was separated and washed with 1M NaHC03. Solvent was dried with Na2S04, filtered and concentrated in vacuo to yield ((tert-butoxycarbonyl)azanediyl)bis(propane-3, l-diyl) ditetradecanoate as an oil that was carried forward without further purification.
Step 4: Preparation of Intermediate 4: azanediylbis(propane-3,l-diyl) ditetradecanoate TFA salt
Figure imgf000024_0001
[0094] ((tert-butoxycarbonyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate (11.3 g, 17.3 mmol) was dissolved in TFA/CHC13 (1 : 1, 20 mL) and the mixture was allowed to stir at room temperature for 15 minutes. Material was then concentrated in vacuo. This was repeated a second time. Material was then dissolved in DCM and washed with H20, dried with Na2S04, concentrated in vacuo and dried fully overnight. The reaction mixture was concentrated.
Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded azanediylbis(propane-3,l-diyl) ditetradecanoate TFA salt (7.5 g).
Step 5: Preparation ofi-Pr-DC: ((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l-diyl) ditetradecanoate
Figure imgf000024_0002
[0095] Azanediylbis(propane-3,l-diyl) ditetradecanoate TFA salt (750 mg, 1.35 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of N,N-dimethylglycine (154 mg, 1.49 mmol), HATU (616 mg, 1.62 mmol) and DIEA (495 uL, 2.84 mmol) in DCM (5 mL). Flask was flushed with argon and allowed to stir at room temperature overnight. The reaction mixture was concentrated. Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded ((2-(dimethylamino)acetyl)azanediyl)bis(propane-3, l-diyl) ditetradecanoate (465 mg). QTOF MS ESI+: m/z 639.6 (M + H).
[0096] Preparation of (Z)-((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l- diyl) dioleate
(i-Pr-DOPC)
Figure imgf000025_0001
Step 1: Preparation of Intermediate 1: 3,3'-azanediylbis(propan-l-ol
H2N^^OH + CI^^^OH ► HO^^N^^^OH
H
[0097] A mixture of 3-amino-l-propanol (14.5 mL, 19.0 mmol), l-chloro-3 -hydroxy propane (8.00 mL, 95.6 mmol) and water (50 mL) was refluxed over 24 hours. Potassium hydroxide (5.40 g) was then added. After dissolution, the whole of the water was evaporated to leave a viscous oil and large quantities of potassium chloride. These were filtered and washed with dry acetone and dichloromethane. The organic phase was dried over a2S04, filtered and evaporated to leave an oil. Purification by silica gel chromatography eluating with a
DCM/MeOH gradient yielded 3,3'-azanediylbis(propan-l-ol) (12.5g).
Step 2: Prep : tert-butyl bis(3-hydroxypropyl)carbamate
Figure imgf000025_0002
'
Boc
[0098] 3,3'-azanediylbis(propan-l-ol) (12.5 g, 95.4 mmol) was diluted in DCM (25 mL). A solution of di-tert-butyl dicarbonate (26.0 g, 119 mmol) in DCM (25 mL) was slowly added while stirring under a blanket of Ar gas. Reaction was allowed to stir overnight. The reaction mixture was concentrated. Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded tert-butyl bis(3-hydroxypropyl)carbamate.
Step 3: Preparation of Intermediate 3: (Z)-((tert-butoxycarbonyl)azanediyl)bis(propane-3,l- diyl) dioleate
Figure imgf000025_0003
[0099] tert-butyl bis(3-hydroxypropyl)carbamate, triethylamine and DMAP were dissolved in chloroform. While being stirred in an ice-bath, a solution of oleyl chloride was added over 15 minutes. The addition was carried out in such a way that the temperature of the reaction did not exceed 30°C. The reaction was allowed to stir at room temperature overnight. Next day, MeOH (50 mL) and 0.9% saline solution (50mL) was added to quench the reaction. The organic layer was separated and washed with 1M NaHC03. Solvent was dried with Na2S04, filtered and concentrated in vacuo to yield (Z)-((tert-butoxycarbonyl)azanediyl)bis(propane-3, l- diyl) dioleate as an oil that was carried forward without further purification.
Figure imgf000026_0001
[0100] (Z)-((tert-butoxycarbonyl)azanediyl)bis(propane-3, l-diyl) dioleate (13.2 g, 17.3 mmol) was dissolved in TFA/CHC13 (1 : 1, 20 mL) and the mixture was allowed to stir at room temperature for 15 minutes. Material was then concentrated in vacuo. This was repeated a second time. Material was then dissolved in DCM and washed with FLO, dried with a2S04 and concentrated in vacuo. Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded (Z)-azanediylbis(propane-3,l-diyl) dioleate TFA salt.
Step 5: Preparation of i-Pr-DODC: (Z)-((2-(dimethylamino)acetyl)azanediyl)bis(propane-3,l-
Figure imgf000026_0002
[0101] (Z)-azanediylbis(propane-3, l-diyl) dioleate TFA salt (750 mg, 1.13 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of Ν,Ν-dimethylglycine (128mg, 1.24mmol), HATU (517mg, 1.36mmol) and DIEA (413uL, 2.37mmol) in DCM (5mL). Flask was flushed with argon and allowed to stir at room temperature overnight. The reaction mixture was concentrated. Purification by silica gel chromatography eluating with a DCM/MeOH gradient yielded (Z)-((2-(dimethylamino)acetyl)azanediyl)bis(propane-3, l-diyl) dioleate (450 mg). QTOF MS ESI+: m/z 747.7 (M + H). [0102] Preparation of ((2-(dimethylamino)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate, (l-DC)
Figure imgf000027_0001
Step 1: Preparation of Intermediate 1: ((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate
Figure imgf000027_0002
[0103] N-Boc diethanolamine (MW 205.25; 8.4 g, 0.041 mole), triethylamine (MW 101.19; 11.5 ml, 0.083 mol) and 4-(dimethylamino)pyridine (MW 122.17; 1.3 g, 0.01 1 mole) were dissolved in chloroform (170 mL). While being stirred in an ice/water bath, a solution of myristoyl chloride (MW 246.82; 22 mL, 80.9 mmol) in 100 mL of chloroform was added dropwise. The reaction mixture was then taken out of the cold bath, and the stirring was continued at room temperature for 2 h. A mixture of 200 mL of methanol and 200 ml of 0.9% saline was added to quench the reaction. The stirring was stopped and the organic layer was isolated. The solvent was removed by rotary evaporation to afford ((tert- butoxycarbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate as a colorless oil (25.7 g) that was carried forward without further purification.
Step 2: Preparation of Intermediate 2: azanediylbis(ethane-2,l-diyl) ditetradecanoate TFA salt
Figure imgf000027_0003
[0104] To a solution of ((tert-butoxycarbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate (33.0 g, 0.053 mole) in 100 ml of chloroform was added trifluoroacetic acid (150 mL, 2.02 mol). The reaction mixture was stirred at room temperature overnight. After the solvent was removed by rotary evaporation, the resultant soft solid was recrystallized from 80 ml of methanol to yield azanediylbis(ethane-2,l-diyl) ditetradecanoate TFA salt (16.6 g) as a white solid. Step 3: Preparation of i-DC: ((2-(dimethylamino)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate
Figure imgf000028_0001
[0105] Azanediylbis(ethane-2, l-diyl) ditetradecanoate TFA salt(10g, 16 mmol) was diluted with dimethylglycine (42.5g, 25 mmol), DCC (4.7 g, 23 mmol) and DIEA (6.33 mL, 40 mmol) in Pyridine (20 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was heated at 55°C overnight. Next day, the reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated to yield ((2-(dimethylamino)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate.
[0106] Preparation of ((3-(dimethylamino)propanoyl)azanediyl)bis(ethane-2,l- diyl) ditetradecanoate (i-Et-DC, also referred to herein as Etl04)
Figure imgf000028_0002
[0107] Preparation of i-Et-DC: ((3-(dimethylamino)propanoyl)azanediyl)bis(ethane- 2,1-diyl) ditetradecanoate
Figure imgf000028_0003
[0108] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1.50 g, 2.85 mmol) was diluted with DCM (10 mL) and added to a pre-activated mixture of 3-(dimethylamino)propionic acid HCl salt (482 mg, 3.14 mmol), HATU (1.30 g, 3.42 mmol) and DIEA (1.04 mL, 5.98 mmol) in DCM (10 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 niL) and 10% K2C03 (20 niL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO rnL). The combined organics were stirred with MgSC^ for 30 min at 0-5°C, filtered, washed with DCM, and concentrated to yield ((3-(dimethylamino)propanoyl)azanediyl)bis(ethane-2, l-diyl) ditetradecanoate (1.01 g). QTOF MS ESI+: m/z 625.6 (M + H).
[0109] Preparation of (Z)-((3-(dimethylamino)propanoyl)azanediyl)bis(ethane-2,l- diyl) dioleate
i-Et-DODC
Figure imgf000029_0001
Step 1: Preparation of Intermediate 1: (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-
Figure imgf000029_0002
[0110] N-Boc diethanolamine (17.8 g, 0.087 mole), triethylamine (24.4 mL, 0.176 mole) and 4- (dimethylamino)pyridine (2.76 g, 0.023 mole) were dissolved in 350 ml of chloroform. While being stirred, a solution of oleyl chloride (61.6 g, 0.174 mole) in 100 ml of chloroform was added over 10 min (Alternatively, the chloroform solution of N-Boc
diethanolamine was immersed in an ice/water bath while oleyl chloride was added). The addition was carried out in such a way that the temperature of the reaction mixture does not exceed 50°C. The reaction mixture was stirred at room temperature for 2 hrs. A mixture of 200 ml of methanol and 200 ml of 0.9% saline was added to quench the reaction. The organic layer was separated and washed with 2 x 100 ml of dilute aqueous sodium bicarbonate. The solvent was removed by rotary evaporation to afford (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2, l-diyl) dioleate as a pale yellow oil (59.5 g). This material was used for the next step without further purification. 1H NMR (400 MHz, CDC13) 0.87 (t,6H, CH3), 1.20-1.40 (m, 40H, CH2), 1.45 (s, 9H, tBu CH3), 1.59 (m, 4H, CH2CH2C(=0)), 2.00(m, 8H, CH2CH=CH), 2.33 (t, 4H, CH2C(=0)), 3.48
(m, 4H, NCH2CH20), 4.18 (m, 4H,NCH2CH20), 5.33 (m, 4H, CH=CH).
Figure imgf000030_0001
[0111] (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2, l-diyl) dioleate (59.5 g, 0.081 mole) was treated twice with 100 ml trifluoroacetic acid (100 mL, 1.35 mol) and 100 ml of chloroform. Each consisted of stirring at room temperature for 10 min, and the solvent was removed by rotary evaporation at the end of each treatment. The residue was dissolved in 200 ml of methylene chloride and the mixture had been washed with 100 ml of water twice. The residue was purified by the silica gel chromatography using a mixture of methanol and methylene chloride as eluent to yield (Z)-azanediylbis(ethane-2,l-diyl) dioleate TFA salt (44.0 g). 1H NMR (400 MHz, CDC13) 0.87 (t, 6H, CH3), 1.20-1.40 (m, 40H, CH2), 1.59 (m, 4H,
CH2CH2C(=O)),2.00 (m, 8H, CH2CH=CH), 2.33 (t, 4H, CH2C(=0)), 3.31 (m, 4H, NCH2CH20), 4.38 (m, 4H, NCH2CH20), 5.33 (m, 4H, CH=CH).
Step 3: Preparation ofi-Et-DODC: (Z)-((3-(dimethylamino)propanoyl)azanediyl)bis(ethane- 2, -diyl) dioleate
Figure imgf000030_0002
[0112] (Z)-azanediylbis(ethane-2, l-diyl) dioleate TFA salt (1.50 g, 2.37 mmol) was diluted with DCM (10 mL) and added to a pre-activated mixture of 3-(dimethylamino)propionic acid HC1 salt (383mg, 2.49 mmol), HATU (1.03 g, 2.72 mmol) and DIEA (831 uL, 4.77 mmol) in DCM (10 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 mL) and 10% K2C03 (20 mL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO mL). The combined organics were stirred with MgS04 for 30 min at 0-5 C, filtered, washed with DCM, and concentrated to yield (Z)-((3-(dimethylamino)propanoyl)azanediyl)bis(ethane-2, l-diyl) dioleate. QTOF MS ESI+: m/z 733.6 (M + H). [0113] Preparation of ((4-(dimethylamino)butanoyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate [i-Prop-DC (also referred to herein as Prl04)l
Figure imgf000031_0001
[0114] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1.00 g, 1.90 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of 4-(Dimethylamino) butyric acid HCl salt (382 mg, 2.28mmol), HATU (867 mg, 2.28 mmol) and DIEA (728 uL, 4.18 mmol) in DCM (5 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 mL) and 10% K2C03 (20 mL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO mL). The combined organics were stirred with MgS04 for 30 min at 0-5oC, filtered, washed with DCM, and concentrated to yield ((4-(dimethylamino)butanoyl)azanediyl)bis(ethane-2, 1-diyl) ditetradecanoate. LCMS ESI+: m/z 639.6 (M + H).
[0115] Preparation of (Z)-((4-(dimethylamino)butanoyl)azanediyl)bis(ethane-2,l- diyl) dioleate
[i-Prop-DODC (also referred to herein as Prl04-DO)l
Figure imgf000031_0002
Figure imgf000032_0001
[0116] Synthesis of (Z)-azanediylbis(ethane-2, 1 -diyl) dioleate TFA salt previously described. (Z)-azanediylbis(ethane-2, l-diyl) dioleate TFA salt (1.00 g, 1.58 mmol) was diluted with DCM (5 mL) and added to a pre-activated mixture of 4-(Dimethylamino) butyric acid HC1 salt (317 mg, 1.89 mmol), HATU (719 mg, 1.89 mmol) and DIEA (606 uL, 3.48 mmol) in DCM (5 mL). The round-bottomed flask was flushed with argon gas and the reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled fractions were concentrated and stirred in DCM (20 mL) and 10% K2C03 (20 mL) at 0-5°C for 30 min. The organic layer was isolated and the aqueous layer further extracted with DCM (2 xlO mL). The combined organics were stirred with MgS04 for 30 min at 0-5°C, filtered, washed with DCM, and concentrated to yield (Z)-((4-(dimethylamino)butanoyl)azanediyl)bis(ethane-2, l-diyl) dioleate. LCMS ESI+: m/z 747.7 (M + H).
[0117] Preparation of (Ζ)-((2-((2- dimethylamino)ethyl)thio)acetyl)azanediyl)bis ethane-2,l-diyl) dioleate (S104-DO)
Figure imgf000032_0002
[0118] Synthesis of (Z)-azanediylbis(ethane-2, 1-diyl) dioleate TFA salt previously described. (Z)-azanediylbis(ethane-2, 1-diyl) dioleate TFA salt (4.06 g, 6.41 mmol) was stirred in DCM (60 mL) with 10% K2C03 (30 mL) at 0-5°C. After 30 min, the organic phase is separated and the aqueous phase was further extracted with DCM (30 mL). The combined organic phases are stirred with MgS04 for a period of 30 min at 0-5°C, filtered and washed with DCM (~30 mL). To the combined filtrates were added 2-((2-(dimethylamino)ethyl)thio)acetic acid (1.26 g, 7.70 mmol), EDC HC1 salt (1.84 g, 9.62 mmol), DMAP (78.3 mg, 0.64 mmol) and the thin suspension was stirred overnight at room temperature. Next day, ¾0 (60 mL) and MeOH (30 mL) are added and after stirring for 10 min, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM. The combined organic extracts are concentrated. Crude material was filtered through a plug of silica and taken up in DCM (40 mL) and PBS (pH=l 1, 50mL) was added. The mixture was stirred at room temperature for ~10 min.
Afterwards, the organic phase was separated and the aqueous phase was extracted again with DCM (15 mL). The combined organics are dried (MgS04) for 30 min, filtered, washed with DCM, and concentrated to yield (Z)-((2-((2-
(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) dioleate (3.44 g). LCMS ESI+: m/z 780.2 (M + H).
[0119] Preparation ((5-(dimethylamino)pentanoyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (C104)
Figure imgf000033_0001
[0120] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (730 mg, 1.14 mmol) was stirred in DCM (20 mL) with 10% K2C03 (10 mL) at 0-5 °C. After 30 min, the organic phase was separated and the aqueous phase was further extracted with DCM (10 mL). The combined organic phases are stirred with MgS04 for a period of 30 minutes at 0-5°C, filtered and washed with DCM (10 mL). To the combined filtrates are added 5-(dimethylamino)pentanoic acid (248 mg, 1.37 mmol), EDC HCl salt (328 mg, 1.71 mmol), DMAP (14 mg, 0.1 14 mmol) and the thin suspension was stirred overnight at room temperature, after which the solution becomes clear. Next day, FLO (20mL) and MeOH (lOmL) are added and after stirring for 10 min, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM. The combined organic extracts are concentrated. After purification by silica gel chromatography by eluating with 100% ethyl acetate followed by 10% MeOH/DCM, the purified residue was taken up in DCM (25mL) and PBS (pH=l 1, 25mL). The mixture was stirred at room temperature for 15 min. Afterwards, the organic phase was separated out and the aqueous phase was extracted again with DCM (15 mL). The combined organics are dried (MgS04) for 30 min, filtered, washed with DCM, and concentrated to yield ((5-
(dimethylamino)pentanoyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (405 mg). LCMS ESI+: m/z 654.1 (M + H).
[0121] Preparation of ((2-((2- (dimethylamino)ethyl)sulfonyl)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetra- decanoate
(SO2-S104)
Figure imgf000034_0001
[0122] Synthesis of ((2-((2-(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2, 1- diyl) ditetradecanoate, aka SI 04, was described. To ((2-((2-
(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate in a round- bottom flask, flushed with argon was added DCM (10 mL). The solution was cooled by an ice- bath. To this, was added mCPBA (a solution in DCM) slowly over 5 min. The ice bath was removed after the addition and the reaction was allowed to stir overnight at room temperature. After 3.5 hours, 2M DMA/THF (4.55 mL) was slowly added and the reaction mixture was allowed to stir overnight. The reaction mixture was then diluted with DCM to 75 mL. Washed with H20 (2 x 50 mL) and 10% K2C03 (50 mL). Back extracted all aqueous washes with DCM (40 mL). The combined organics were dried (MgS04), filtered, and concentrated to yield a colorless oil. The reaction mixture was concentrated. Purification by silica gel chromatography eluating with a ethyl acetate/MeOH gradient yielded ((2-((2-
(dimethylamino)ethyl)sulfonyl)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (540 mg). LCMS ESI+: m/z 704.0 (M + H). [0123] Preparation of ((((2- (dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (TU104)
Figure imgf000035_0001
[0124] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt was dissolved in DCM (50 mL) and PBS (pH=l 1, 50mL) was added. The mixture was stirred at room temperature for 15 min. Afterwards, the organic phase separated and the aqueous phase extracted again with DCM (25 mL). The combined organics were dried (MgS04) for 30 min, filtered, washed with DCM, and concentrated to yield azanediylbis(ethane-2, 1-diyl) ditetradecanoate as the free base.
Step 2: Preparation of TU104: ((((2-
Figure imgf000035_0002
[0125] Trichloromethyl chloroformate (aka diphosgene) (257 uL, 2.13 mmol) was added to a solution of 2-(dimethylamino)ethanethiol HC1 salt (302 mg, 2.13 mmol) in dry DCM (20 mL) and stirred under a blanket of argon at room temperature for 4 h. Afterwards, DCM and excess diphosgene were removed in vacuo. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate free base (1068 mg, 2.03 mmol), DCM (20 mL) and triethylamine (580 uL, 4.16 mmol) were then added. After 16 h at room temperature the reaction mixture was diluted with DCM and washed with 1M HC1 (75 mL), H20 (75 mL) and PBS (pH=l 1, 75mL), dried (MgS04), filtered, and concentrated. Purification by silica gel chromatography eluating with ethyl acetate followed by a DCM/MeOH gradient yielded ((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane- 2, 1-diyl) ditetradecanoate (120 mg). LCMS ESI+: m/z 657.5 (M + H).
[0126] Preparation of ((2-(2-(dimethylamino)ethoxy)acetyl)azanediyl)bis(ethane- 2,1-divf) ditetradecanoate (Ό104)
Figure imgf000036_0001
[0127] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1500mg, 2.34mmol) was dissolved in DCM (20mL) and placed in an ice-bath. Bromoacetyl bromide (214uL, 2.46mmol) was added followed by triethylamine(685uL, 4.91 mmol). The ice-bath was removed and the reaction was allowed to stir overnight at room temperature under a blanket of inert gas. Next day, diluted with DCM to lOOmL. Washed with 1M HCl(75mL), H20 (75ml), saturated aHC03 solution (75mL) and saturated brine solution (75mL). Back extracted all aqueous washes with DCM (25mL). Dried organincs with MgS04, filtered and concentrated in vacuo. Purified by silica gel chromatography and eluating with 100% ethyl acetate. Pooled and concentrated fractions to yield ((2-bromoacetyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate (1220mg).
Step 2: Preparation of O104: ((2-(2-(dimethylamino)ethoxy)acetyl)azanediyl)bis(ethane-2,l-
Figure imgf000036_0002
[0128] To a round-bottom flask equipped with stir bar, was added ((2- bromoacetyl)azanediyl)bis(ethane-2, l-diyl) ditetradecanoate (1.22 g, 1.87 mmol), N,N- dimethylethanolamine (197 uL, 1.96 mmol), potassium iodide (6.2 mg, 0.0374 mmol) and dry THF (25 mL). The resulting solution was cooled to -40°C. DBU (588 uL, 3.93 mmol) was added dropwise over 5 min and the reaction was warmed to 0°C for 2 hours. The reaction mixture was concentrated. The residue was taken up with DCM, 1M HC1 (12 mL) was added, and biphasic mixture stirred for 15 min. Then, basified using PBS (pH=l 1). The organic layer was isolated, dried (MgS04), filtered and concentrated. Purification by silica gel chromatography eluating with 100% ethyl acetate followed by a DCM/MeOH gradient yielded ((2-(2- (dimethylamino)ethoxy)acetyl)azanediyl)bis(ethane-2, l-diyl) ditetradecanoate (53 mg). LCMS ESI+: m/z 655.6 (M + H).
[0129] Preparation οΓ ((2-((4- (dimethylamino)butanoyl)oxy)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetra-decanoate
(HEDC-M1)
Figure imgf000037_0001
Step 1: Preparation of Intermediate 1: ((2-(benzyloxy)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecan oate
Figure imgf000037_0002
[0130] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt was stirred in DCM (25 mL) with 10% K2CO3 (12.5 mL) at 0-5°C. After 30 min, the organic layer was isolated and the aqueous layer was further extracted with DCM (12 mL). The combined organic phases are stirred with MgS04 for 30 min at 0-5°C, filtered, washed with DCM (12 mL). To the combined filtrates are added benzyloxy acetic acid (402 uL, 2.81 mmol), EDC HC1 salt (673 mg, 3.51 mmol), and DMAP (29 mg, 0.234 mmol). The suspension was allowed to stir at room temperature overnight. Next day, ¾0 (25 mL) and MeOH (12 mL) was added and after stirring for 10 min the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM (25 mL). The combined organic extracts dried with MgS04, filtered and concentrated. Purification by silica gel chromatography eluating with a hexanes/ethyl acetate gradient yielded ((2-(benzyloxy)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (1.28 g).
Step 2: Preparation of Intermediate 2: ((2-hydroxyacetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate
Figure imgf000038_0001
[0131] ((2-(benzyloxy)acetyl)azanediyl)bis(ethane-2, l-diyl) ditetradecanoate (1.28 g, 1.80 mmol) was dissolved in a round-bottom flask with MeOH (20 mL). The flask was capped and flushed with argon. 10% Pd/C (135 mg) was added and the flask was once again flushed with argon. All air was removed via vacuum pump and then a 8" balloon filled with ¾ gas was added. Reaction was allowed to stir vigorously at room temperature. After 30 min, the reaction mixture was filtered (celite), washed with methanol, concentrated to residue, taken up in DCM (25mL) and 10% K2CO3 (25mL). The mixture was stirred for 15 min and then the organic layer isolated. The aqueous wash was back extracted with DCM (15 mL). The combined organics were dried with MgS04, filtered and concentrated to yield ((2- hydroxyacetyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate (990 mg).
Step 3: Preparation of HEDC-M1: ((2-((4-
Figure imgf000038_0002
[0132] ((2-hydroxyacetyl)azanediyl)bis(ethane-2, l-diyl) ditetradecanoate (990 mg, 1.70 mmol) was stirred in DCM (20 mL) and 4-Dimethylamino-butyric acid (268mg), EDC HC1 salt (487mg) and DMAP (21mg) was added. The suspension was allowed to stir at room temperature overnight. Next day, ¾0 (20mL) and MeOH (lOmL) added and after stirring for 10 minutes the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM (20 mL). The combined organic extracts dried with MgS04, filtered and concentrated. Crude material was purified by silica gel chromatography eluating with a DCM/MeOH gradient. Pooled and concentrated fractions were concentrated and taken up with DCM (25 mL) and PBS (pH = 1 1, 25 mL). The mixture was stirred at room temperature for 15 min. Afterwards, the organic phase was isolated, and the aqueous phase was extracted again with DCM (25 mL). The combined organics are dried (MgS04), filtered, and concentrated to yield ((2-((4-
(dimethylamino)butanoyl)oxy)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (672 mg). LCMS ESI+: m/z 697.6 (M + H).
[0133] Preparation of (Z)-((5-(dimethylamino)pentanoyl)azanediyl)bis(ethane-2,l- divn dioleate iC104-DC»
Figure imgf000039_0001
[0134] Synthesis of (Z)-azanediylbis(ethane-2, 1-diyl) dioleate TFA salt previously described. (Z)-azanediylbis(ethane-2, 1-diyl) dioleate TFA salt (1.50 g, 2.37 mmol) was stirred in DCM (20 mL) with 10% K2C03 (10 mL) at 0-5°C. After 30 min, the organic phase was isolated and the aqueous phase was further extracted with DCM (10 mL). The combined organic phases are stirred with MgS04 for a period of 30 min at 0-5°C, filtered and washed with DCM (15 mL). To the combined filtrates are added 5-(dimethylamino)pentanoic acid (516 mg, 2.84 mmol), EDC HC1 salt (681 mg, 3.55 mmol), DMAP (29 mg, 0.237 mmol) and the suspension was stirred overnight at room temperature, after which period of time became clear solution was formed. Next day, FLO (20 mL) and MeOH (10 mL) added and after stirring for 10 min, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM. The combined organics are dried (MgS04), filtered and concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH gradient, the pooled and concentrated fractions are taken up with DCM (25 mL) and PBS (pH=l 1, 25mL). The mixture was stirred at room temperature for ~10 min. Afterwards, the organic phase was isolated out and the aqueous phase was extracted again with DCM (15 mL). The combined organics are dried (MgS04), filtered, and concentrated to yield (Z)-((5-(dimethylamino)pentanoyl)azanediyl)bis(ethane-2,l-diyl) dioleate (l. lO g). LCMS ESI+: m/z 761.7 (M + H).
[0135] Preparation of ((5-((dimethylamino)methyl)thiophene-2- carbonyl)azanediyl)bis(ethane-2,l-diyr) di-tetradecanoate (T104)
Figure imgf000040_0001
[0136] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1004 mg, 1.57 mmol) was stirred in DCM (20 mL) with 10% K2C03 (20mL) at 0-5°C. After 30 min, the organic phase was isolated and the aqueous phase was further extracted with DCM (10 mL). The combined organics are dried with MgS04 for 30 min at 0-5°C, filtered and washed with DCM (10 mL). To the combined filtrates were added ((dimethylamino)methyl)thiophene-2-carboxylic acid (350 mg, 1.89 mmol), EDC HCl salt (452 mg, 2.36 mmol), and DMAP (19.2 mg, 0.157 mmol). The suspension was allowed to stir at room temperature overnight. Next day, H20 (20 mL) and MeOH (10 mL) were added and after stirring for 10 min, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM (25 mL). The combined organics were dried (MgS04), filtered, and concentrated. After purification by silica gel chromatography eluating with a hexanes/ethyl acetate gradient, the pooled and concentrated fractions were taken up with DCM (20 mL) and PBS (pH=l 1, 20mL). The mixture was stirred at room temperature for ~10 min. Afterwards, the organic phase was isolated and the aqueous phase was extracted again with DCM (15 mL). The combined organics was dried (MgS04) for a period 30 min, filtered, washed with DCM, and concentrated to yield ((5-((dimethylamino)methyl)thiophene-2- carbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate (482 mg). LCMS ESI+: m z 693.6 (M + H). [0137] Preparation of fZHfff2- (dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2,l-diyl) dioleate (TU104-DO)
Figure imgf000041_0001
[0138] Synthesis of (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2, 1 -diyl) dioleate previously described. (Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2, l-diyl) dioleate (4.20 g, 5.72 mmol) was dissolved in DCM (20 mL) and cooled to 0°C in an ice bath. TFA (20 mL) was added and the mixture was allowed to stir under a blanket of inert gas for 20 min. Afterwards, the reaction mixture was concentrated in vacuo. The residue was partitioned between 10% K2CO3 (20 mL) and DCM (20 mL), and stirred in an ice bath for 20 min. The organic layer was isolated, dried (MgS04), and filtered. Diphosgene (1.38 mL, 1 1.4 mmol) was added to (Z)- azanediylbis(ethane-2, l-diyl) dioleate material in DCM and stirred under a blanket of inert gas at room temperature. Next day, DCM and excess diphosgene were removed in vacuo. 2- (dimethylamino)ethane thiol HC1 salt (4.05 g, 28.6 mmol) was taken up in DCM (50 mL) and triethylamine (5.2 mL, 37.2 mmol) and added to (Z)-((chlorocarbonyl)azanediyl)bis(ethane-2, 1 - diyl) dioleate residue. Material was allowed to stir overnight at room temperature. Next day, diluted with DCM and washed with 0.3M HC1 (75 mL), H20 (75 mL) and 10% K2C03 (75 mL). Back extracted all aqueous washes with DCM (25 mL). The combined organics were dried over MgS04, filtered and concentrated. Purification by silica gel chromatography eluating with DCM/MeOH gradient yielded (Z)-((((2-
(dimethylamino)ethyl)thio)carbonyl)azanediyl)bis(ethane-2, l-diyl) dioleate (1.90 g). LCMS ESI+: m/z 765.7 (M + H). [0139] Preparation of g(3- (dimethylamino)propoxy)carbonyl)azanediyl)bis(ethane-2,l-diyl) ditetradeca-noate (CB104)
Figure imgf000042_0001
[0140] Synthesis of azanediylbis(ethane-2, 1 -diyl) ditetradecanoate previously described. Diphosgene (266 uL, 2.2 mmol) was added to dimethylaminopropanol (413 mg, 4.00 mmol) in DCM (10 mL) and stirred under a blanket of inert gas at room temperature for 4 h. The DCM and excess diphosgene was removed in vacuo and azanediylbis(ethane-2,l-diyl) ditetradecanoate was added. The round-bottom flask was flushed with argon and DCM (10 mL) and triethylamine (859 uL, 6.16 mmol) was added. Material was allowed to stir overnight at room temperature. The reaction mixture was then diluted with DCM and washed with 0.3M HCl (75 mL), H20 (75 mL) and 10% K2C03 (75 mL). Back extracted all aqueous washes with DCM (25 mL). The combined organics were dried over MgS04, filtered and concentrated. Purification by silica gel chromatography eluating with DCM/MeOH gradient yielded (((3- (dimethylamino)propoxy)carbonyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (87 mg). ). LCMS ESI+: m/z 655.59 (M + H).
[0141] Preparation of (((2-(dimethylamino)ethoxy)carbonyl)azanediyl)bis(ethane-
2.1-divn ditetradecanoate TCA104)
Figure imgf000042_0002
Step 1: Preparation of Intermediate 1: (((4-nitrophenoxy)carbonyl)azanediyl)bis(ethane-2,l- diyl) ditetradeca-noate
Figure imgf000043_0001
[0142] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt was dissolved in dry DCM (10 mL) and triethylamine (654 uL, 4.69 mmol) was added. The reaction vessel was flushed with inert gas and 4-nitrophenyl chloroformate was added. Material was allowed to stir at RT overnight. The reaction mixture was quenched with water (50 mL) and DCM (50 mL). The organic layer was isolated, and the aqueous layer was extracted further with DCM (2 x 50 mL). The combined organics were dried over MgS04, filtered and concentrated. Purification by silica gel chromatography eluating with hexanes/ethyl acetate gradient yielded (((4- nitrophenoxy)carbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate.
Step 2: Preparation of CA104: (((2-(dimethylamino)ethoxy)carbonyl)azanediyl)bis(ethane- -diyl) ditetra-decanoate
Figure imgf000043_0002
[0143] To (((4- nitrophenoxy)carbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate, was added 2-dimethylaminoethanol (2 mL) and heated to 140°C with a condensing column for 20 min. Afterwards, the crude material was purified by silica gel chromatography eluating with a DCM/MeOH gradient to yield (((2-(dimethylamino)ethoxy)carbonyl)azanediyl)bis(ethane-2, l- diyl) ditetradecanoate (38 mg). LCMS ESI+: m/z 641.7 (M + H).
Preparation of ((2-(dimethylamino)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradecanoate (INT-4)
Figure imgf000043_0003
[0144] Synthesis of (Z)-((2-(dimethylamino)acetyl)azanediyl)bis(ethane-2, 1-diyl) dioleate was was prepared in similar fashion as i-Prop-DODC with the substitution of dimethylglycine for 3-(dimethylamino)propionic acid. QTOF MS ESI+: m/z 720.1 (M + H).
[0145] Preparation οΓ ((2-((2-
(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) ditetradeca-noate (S104)
Figure imgf000044_0001
Step 1: Preparation of intermediate 1: 2-((2-(dimethylamino)ethyl)thio) acetic acid hydrochloride:
Figure imgf000044_0002
[0146] Ethanol (500 mL) was degassed by three times evacuation to 60 mBar for 1-2 minutes and repressurizing with nitrogen. Chloroacetic acid (36.9 g, 0.391 mol) was added and a clear solution was formed after having stirred for 5 minutes at 17-20°C. 2-(Dimethylamino)- ethanethiol hydrochloride (52.7 g, 0.372 mol) was added, and a clear solution was formed after having stirred for 20 minutes at 25°C. Solid sodium hydroxide (47.7 g, 1.19 mol) was added in portions over a period of 20 minutes with cooling in order to keep the temperature below 35°C - a short period at 44°C was observed. Almost immediate precipitation was observed. The reaction mixture was eventually heated and stirred at 40°C for a period of two hours, at which point TLC indicated completion of reaction. Celite 545 (74 g) was added, and the mixture was filtered through a G3 glass-sintered plate over 6 minutes, washing with ethanol (2 x 105 mL). The combined cloudy filtrates are evaporated from a 50°C bath to give 1 10 g of white solid. The solid was dissolved in water (250 mL) then the pH was adjusted from 13.1 (temp. 30°C) to 10.5 (temp 31°C), using concentrated HCl (5.5 mL) to give a very pale yellow solution. The aqueous phase was washed with DCM (3x 100 mL) to remove the disulphide impurity (all 3 washes required). Concentrated HCl was added to the aqueous phase (pH 10.7, temp. 22°C) until the pH was 1.4 (57.5 mL added, temp. 35°C). The aqueous phase was washed with DCM (100 mL) and then concentrated to dryness (bath temperature 55°C). Toluene (250 mL) was added, the mixture was concentrated to dryness (bath temperature 55°C) and this was repeated once to give a wet white solid (98 g). Acetonitrile (750 niL) was added to the solid, the mixture was stirred at 55°C for a period of 45 minutes, and then filtered through a G3 glass-sintered plate. Acetonitrile (250 mL) was added to the filter cake, the mixture was stirred at 55°C for a period of 25 minutes and then filtered through a G3 glass-sintered plate, washing with acetonitrile (50 mL). The combined filtrates are concentrated to 300 mL, resulting in a heavy, white precipitate. The mixture was cooled under nitrogen and stirred at 0°C for a period of 30 minutes. The precipitate was isolated by filtration through a G3 glass sintered plate, and the filter cake was washed with cold acetonitrile (100 mL). Drying under reduced pressure for 3 days gives 47.0 g (63%) of 2-((2- (dimethylamino)ethyl)thio)acetic acid hydrochloride
Step 2: Preparation ofS104: ((2-((2-(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane- -diyl) ditetradecanoate
Figure imgf000045_0001
[0147] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (152 g, 238 mmol) was stirred with DCM (2.3 L) and 10% potassium bicarbonate (1.15 L) at 0-5°C. The organic phase was separated and the aqueous phase was further extracted with DCM (1.15 L). The combined organic phases were stirred with magnesium sulfate hydrate (236 g) for a period of 30 minutes at
0-5°C, filtrated and washed with DCM (1.15 L). To the combined filtrates was added 2-((2-
(dimethylamino)ethyl)thio)acetic acid hydrochloride (57.0 g, 285 mmol), EDC hydrochloride
(68.4 g, 357 mmol) and DMAP (2.91 g, 23.8 mmol), and the thin suspension was stirred overnight at ambient temperature, after which period of time a clear solution was formed, water
(2.3 L) and methanol (460 mL) are added and after having stirred for a period of 10 minutes the clear organic phase was separated. The turbid aqueous phase (pH 3.0) was extracted with DCM
(575 mL). The combined organic extracts were concentrated yielding 143 g of crude material as the hydrochloride salt. The crude material (142.6g) was transferred to a distillation flask with
DCM (500 mL), and ethyl acetate (1 L) was added. The solution was heated to distillation at atmospheric pressure, and distillation was continued over a period of 70 minutes in order to obtain a temperature of the residue of 76°C. A total volume of 1.4 L was obtained by addition of ethyl acetate (800 mL), and ethanol (70 mL) was added. The clear solution at 50°C was cooled to
37°C and seed crystals were added. Having observed initiation of significant crystallization over a period of 10 minutes at 37-35°C, the suspension was cooled and stirred at 0°C overnight and the precipitate was isolated by filtration, and washed with cold ethyl acetate (210 mL). Drying to a constant weight at ambient temperature in oil pump vacuum over a period of 4.5 hours gave 134 g of recrystallized material as the hydrochloride salt, white crystalline solid.
[0148] Tripotassium phosphate (85 g, 0.40 mol) and dipotassium hydrogen phosphate (226 g, 1.30 mol) were added to purified water (1.7 L), and the solution formed with pH 10.9 was cooled to 18-20°C. DCM (1.3 L) and recrystallized S104 hydrochloride (133.0 g, 0.188 mol) are added, and the mixture was stirred for a period of 10 min minutes. A clear organic phase was separated at moderate rate (over a period of 35 minutes), and the turbid aqueous phase was further extracted with DCM (650 mL). The combined organic phases were stirred with magnesium sulfate hydrate (65 g) for a period of 40 minutes, and the mixture was filtered, washing with DCM (200 mL). The combined filtrates were evaporated from a 50°C water bath under reduced pressure (down to 20 mBar, at which pressure evaporation was continued for one hour). Additional evaporation from a 15-20°C water bath at oil pump vacuum, resulted in 126 g partially solidified oil. Cooling in -20°C cooling bath gave complete solidification, and after drying at -20°C under vacuum for two days we obtained 126 g of ((2-((2-
(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate , also known as S 104. HPLC indicates 98.1% purity. QTOF MS ESI+: m/z 671.6 (M + H).
[0149] Preparation of (9Z,9'Z)-((2-((2- dimethylamino)ethyl)thio)acetyl)azanediyl)bis ethane-2,l-diyl) bis(tetradec-9-enoate)
(S104-DMO)
Figure imgf000046_0001
Step 1: Preparation of Intermediate 1: (9Z,9'Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane- -diyl) bis( tetradec-9-enoate)
Figure imgf000046_0002
[0150] N-Boc-diethanolamine (454 mg, 2.21 mmol), myristoleic acid (1000 mg, 4.42 mmol) and DMAP (54 mg, 0.442 mmol) was dissolved in DCM (25 mL) and placed in a water bath at ambient temperature in a round-bottom flask was flushed with inert gas. EDC HC1 salt (932 mg, 4.86 mmol) was added in 3 portions over 5 min. The reaction was allowed to stir overnight at room temperature under a blanket of inert gas. Next day, added FLO (25 mL) and stirred for 10 min. The organic layer was isolated and the aqueous layer was further extracted with DCM (50 mL). The combined organics were dried (MgS04) for 10 min, filtered and concentrated. Purification by silica gel chromatography eluating with a hexane/ethyl acetate gradient yielded (9Z,9'Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-diyl) bis(tetradec-9- enoate) (1.10 g).
Step 2: Preparation of Intermediate 2: (9Z,9'Z)-azanediylbis(ethane-2,l-diyl) bis(tetradec-9- enoate
Figure imgf000047_0001
[0151] To (9Z,9'Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2, l-diyl) bis(tetradec-9- enoate) (1 100 mg, 1.77 mmol) in a round-bottom flask was added DCM (10 mL) and placed into an ice-bath. TFA (10 mL) was added and the mixture was allowed to stir for 20 min. The reaction mixture was then concentrated. Toluene was added to the residue to aid in azeotroping off excess TFA. The residue was placed back in the ice bath and PBS (pH=l 1, 25mL) and DCM (25mL) were added. The mixture was stirred for 15 min and the organic layer was then isolated. The turbid aqueous layer was extracted with DCM (10 mL). The combined organics were dried (MgS04) at 0°C for 15 min, filtered and concentrated to yield (9Z,9'Z)-azanediylbis(ethane-2, l- diyl) bis(tetradec-9-enoate) (923 mg).
Step 3: Preparation ofS104-DMO: (9Z,9'Z)-((2-((2-
(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) bis(tetradec-9-enoate)
Figure imgf000047_0002
[0152] A mixture of (9Z,9'Z)-azanediylbis(ethane-2, 1 -diyl) bis(tetradec-9-enoate) (923 mg, 1.77 mmol), 2-((2-(dimethylamino)ethyl)thio)acetic acid (346 mg, 2.12 mmol) and EDC HC1 salt (509 mg, 2.66 mmol) suspended in DCM (10 mL). DMAP (21.6 mg, 0.177 mmol) was added and the mixture was allowed to stir at room temperature overnight. Next day, FLO (10 mL) and MeOH (10 mL) was added and after stirring for 10 min, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM (2 x 20 rnL). The combined organic extracts are dried with MgS04, filtered and concentrated. After purification by silica gel chromatography eluating with a DCM/MeOH, the pooled and concentrated fractions were taken up in DCM (25 mL) and PBS (pH=l 1, 25mL). The mixture was stirred at room temperature for -10 min. Afterwards, the organic phase was isolated and the aqueous phase was extracted again with DCM (2 x 15 mL). The combined organics phase were dried (MgS04), filtered, and concentrated to yield (9Z,9'Z)-((2-((2-(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane- 2, 1-diyl) bis(tetradec-9-enoate) (589 mg). LCMS ESI+: m/z 667.6 (M + H).
[0153] Preparation of (R)-((l-methylpyrrolidine-2-carbonyl)azanediyl)bis(ethane-
2,1-diyl) ditetradecanoate (Pro-DC)
Figure imgf000048_0001
Step 1: Preparation of Pro-DC: (R)-((l-methylpyrrolidine-2-carbonyl)azanediyl)bis(ethane-
Figure imgf000048_0002
[0154] Synthesis of azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt previously described. Azanediylbis(ethane-2, 1-diyl) ditetradecanoate TFA salt (1000 mg, 1.56 mmol) was stirred with DCM (10 mL) and N-Methyl-L-Proline (228 mg, 1.77 mmol), HOBtH20 (239 mg, 1.77 mmol) was added. NMM (365 uL, 3.32 mmol) was added and the solution became mostly clear. A suspension of EDC hydrochloride (518 mg, 2.70 mmol), NMM (257 uL, 2.34 mmol) and DMAP (19 mg, 0.156 mmol) in DCM (10 mL) was added and the mixture was stirred for about 12 hours at ambient temperature, after which period of time a clear solution was formed. Thereafter , the mixture was diluted with DCM (50 mL) and washed with 10% K2CO3, aqueous (60 mL). The organics were dried with MgS04, filtered and concentrated. The resulting compound was purified crude by Silica Gel chromatography, eluting with a (0-10)% methanol in DCM gradient to yield (R)-(( 1 -methylpyrrolidine-2-carbonyl)azanediyl)bis(ethane-2, 1 -diyl) ditetradecanoate. LCMS ESI+: m/z 637.6 (M + H). [0155] Preparation of (9Z,9'Z,12Z,12'Z)- 2-((2- (dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) bis(octadeca-9,12-dienoate)
Figure imgf000049_0001
Step 1: Preparation of Intermediate 1: (9Z,9'Z,12Z,12'Z)-((tert-
Figure imgf000049_0002
[0156] N-Boc-diethanolamine (5 g, 24.4 mmol), linoleic acid (14.4 g, 51.2 mmol) and was dissolved in DCM (100 mL). EDC HC1 salt (10.3 g, 53.7 mmol) was added followed by DMAP (596 mg, 4.88 mmol). The reaction was allowed to stir for about 12 hours at room temperature under a blanket of inert gas. Thereafter, 50 mL of water and 50 mL of methanol were added, and the mixture was stirred for 10 min. The organic layer was isolated and the aqueous layer was further extracted with DCM (150 mL). The combined organics were dried (MgS04) for 10 min, filtered and concentrated. Purification was by silica gel chromatography, eluating with a hexane/ethyl acetate gradient yielded (9Z,9'Z, 12Z, 12'Z)-((tert- butoxycarbonyl)azanediyl)bis(ethane-2, l-diyl) bis(octadeca-9,12-dienoate) (15.9 g).
Step 2: Preparation of Intermediate 2: (9Z,9'Z,12Z,12'Z)-azanediylbis(ethane-2,l-diyl)
Figure imgf000049_0003
[0157] To (9Z,9'Z,12Z, 12'Z)-((tert-butoxycarbonyl)azanediyl)bis(ethane-2,l-diyl) bis(octadeca-9, 12-dienoate) (5.33 g, 7.30 mmol) in a round-bottom flask was added DCM (50 mL) and placed into an ice-bath. TFA (50 mL) was added and the mixture was allowed to stir for 30 min. The reaction mixture was then concentrated. Toluene was added to the residue to aid in azeotroping off excess TFA. The residue was placed back in the ice bath and 10% K2CO3 (50mL) and DCM (50mL) were added. The mixture was stirred for 15 min and the organic layer isolated. The turbid aqueous layer was extracted with DCM (20 mL). The combined organics were dried (MgS04), filtered and concentrated to yield (9Z,9'Z, 12Z, 12'Z)-azanediylbis(ethane- 2, 1-diyl) bis(octadeca-9, 12-dienoate) (Quantitative).
Step 3: Preparation ofS104-DLin: (9Z,9'Z,12Z,12'Z)-((2-((2-
Figure imgf000050_0001
[0158] A mixture of (9Z,9'Z, 12Z, 12'Z)-azanediylbis(ethane-2, 1-diyl) bis(octadeca- 9, 12-dienoate) (4.68 g, 7.30 mmol), 2-((2-(dimethylamino)ethyl)thio)acetic acid (1.43 g, 8.76 mmol) and EDC HC1 salt (2.10 g, 10.95 mmol) were suspended in DCM (100 mL). DMAP (89 mg, 0.73 mmol) was added, stirred at room temperature for 12 hours. Fifty mL each of water and methanol were added and, after stirring for 10 minutes, the clear organic phase was isolated. The turbid aqueous phase was extracted with DCM (2 x 20 mL) and washed combined organic extracts with PBS (pH=l 1, lOOmL). The product was dried with MgS04, filtered and concentrated. Purification was by silica gel chromatography eluating with a MeOH in DCM gradient. Pooled and concentrated fractions yielded (9Z,9'Z, 12Z, 12'Z)-((2-((2- (dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2, 1-diyl) bis(octadeca-9, 12-dienoate) (4.3 g). LCMS ESI+: m/z 775.9 (M + H).
[0159] Preparation of (9Z,9'Z,12Z,12'Z)-((2- 2- dimethylamino)ethyl)thio)acetyl)azanediyl)bis ethane-2,l-diyl) bis(octadeca-9,12-dienoate) (TU104-DLin)
Figure imgf000050_0002
Step 1: Preparation of TU104-Dlin: (9Z,9'Z,12Z,12'Z)-((2-((2- azanediyl)bis(ethan
Figure imgf000050_0003
[0160] Synthesis of (9Z,9'Z,12Z, 12'Z)-azanediylbis(ethane-2,l-diyl) bis(octadeca-9, 12- dienoate) previously described. Trichloromethyl chloroformate (aka diphosgene) (740 uL, ) was added to a solution (9Z,9'Z, 12Z, 12'Z)-azanediylbis(ethane-2,l-diyl) bis(octadeca-9, 12-dienoate) (2.6 g) in dry DCM (40 mL) and stirred under a blanket of argon at room temperature for 12 hourrs. DCM and excess diphosgene were removed in vacuo. 2-(dimethylamino)ethane thiol HC1 salt (2.9 g), DCM (40 mL) and triethylamine (3.7 mL) were then added. After 16 h at room temperature the reaction mixture was diluted with DCM and washed with 10% K2CO3 (75mL), dried (MgS04), filtered, and concentrated. Purification was purified by silica gel chromatography eluating with ethyl acetate followed by a DCM/MeOH gradient to yield (9Z,9'Z, 12Z, 12'Z)-((2- ((2-(dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,l-diyl) bis(octadeca-9,12-dienoate) (850 mg). LCMS ESI+: m/z 761.9 (M + H).
[0161] Formation of non-diVA siRNA containing liposomes. lonizable lipid, DOPE, cholesterol, and a PEG-conjugated lipid were solubilized in absolute EtOH (200 proof) at a final weight concentration of ~4.4 mg/mL. The siRNA was solubilized in citrate buffer at a concentration -0.26 mg/mL and the temperature was adjusted to 35-40°C. The ethanol/lipid mixture was then added to the siRNA-containing buffer while stirring to spontaneously form siRNA loaded liposomes. Lipids were combined with siRNA to reach a final total lipid to siRNA ratio of 7: 1 to 14: 1 (w wt). The siRNA loaded liposomes were diafiltered against lOx volumes of PBS to remove ethanol and exchange the buffer. Final product was filtered through 0.22 μιη, sterilizing grade, filter for bioburden reduction. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI <0.2, and >85% RNA encapsulation (entrapment) efficiency.
[0162] Formation of siRNA containing liposomes co-solubilized with diVA^ siRNA- diVA-Liposome formulations were prepared using the method described above. diVA-PEG- diVA was co-solubilized in absolute ethanol with the other lipids (ionizable lipid, DOPE, cholesterol, and PEG-conjugated lipids) prior to addition to the siRNA containing buffer. Molar content of diVA-PEG-diVA ranged from 0.1 to 5 mol%. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI <0.2, and >85% entrapment efficiency.
[0163] Formation of siRNA containing liposomes with ionizable and cationic lipids^ siRNA-diVA-Liposome formulations and siRNA-Liposome formulations were prepared using the method described above. Cationic lipid was co-solubilized in absolute ethanol with the other lipids (ionizable lipid, DOPE, cholesterol, PEG-conjugated lipids, and diVA-PEG-diVA) prior to addition to the siRNA containing buffer. Molar content of cationic lipid ranged from 5 to 40 mol%. This process yielded liposomes with a mean particle diameter of 40-100 nm, PDI <0.2, and >85% entrapment efficiency.
In vitro (pHSC, gp46 KD @ 20 nM) efficacy
[0164] PHSCs in 96-well plate were incubated with formulation that composed of either ionizable lipid formulation CI 04, ionizable lipid formulation Tul04, or combination formulations with different ratio of ionizable lipids (C104:Tul04). After 30 minutes, medium was replaced with fresh growth medium. Forty eight hours later, cells were lysed and gp46 and GAPDH mRNA levels measured by quantitative RT-PCR (TaqMan® ) assay, and gp46 levels were normalized to GAPDH levels. Normalized gp46 levels were expressed as percent of mock control cells. Error bars indicate standard deviations (n=3). Results are depicted in Figure 1. As the results demonstrate, the combination of two ionizable lipids of the description resulted in observed synergistic reduction in gene expression.
[0165] Similar experiments were carried out with other ionizable lipid: ionizable lipid and ionizable lipid: cationic lipid combinations. Results for S104-DO:Tul04-DO combinations are depicted in Figure 2. Results for HEDODC:Tul04 combinations are depicted in Figure 3. Combinations of both ionizable lipids and ionizable:cationic lipids again resulted in synergistic reduction in gene expression.
In vivo (DMNQ) efficacy:
[0166] In vivo activity of target formulation was evaluated in the short-term liver damage model (referred to as the Quick Model or DMNQ). In this model, the short-term liver damage induced by treatment with a hepatotoxic agent such as dimethylnitrosamine (DMN) is accompanied by the elevation of gp46 mRNA levels. To induce these changes, male Sprague- Dawley rats were injected intraperitoneally with DMN on six consecutive days. At the end of the DMN treatment period, the animals were randomized to groups based upon individual animal body weight. Formulations was administered as a single IV dose, one hour after the last injection of DMN. Twenty four hours after, liver lobes were excised and both gp46 and MRPL19 mRNA levels were determined by quantitative RT-PCR (TaqMan) assay. mRNA levels for gp46 were normalized to MRPL19 levels. Results are depicted in Figure 4. Several combinations of ionizable:cationic lipids achieved 50% reduction in gene expression expression for a single, 0.5 mg per kg of animal body weight, dose of encapsulated siRNA. In vitro toxicology data, in vitro cytotoxicity (HepG2 @ 200 nM)
[0167] Addition of 20 mol % of S 104 into formulations of the description improved cell viability in a HepG2 cytotoxicity assay improved from 27 % to 52 %.
Figure imgf000053_0001
HepG2 cytotoxicity assay description:
[0168] HepG2 cells, an adherent cell line derived from human hepatocellular carcinoma, was cultured in MEM/EBSS (Hyclone, Logan, Utah, Cat# SH30024.01)
supplemented with 10% FBS (Hyclone, Logan, Utah Cat# SH30910). HepG2 cells were seeded in 96-well Optilux black plates (BD Falcon, Cat # BD353220) at 5000 cells/well overnight. Formulations were added to each well to final indicated siRNA concentration (n=3). At 48 h post formulation addition, cell viability was determined using CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, Cat #G7572) following manufacture's instruction.
Chemiluminescent signal were measured on Clarity Luminescence Microplate Reader (502- Biotek, Winooski, Vermont). Viability was calculated based on % of chemiluminescent signal in formulation treated well normalized against mock treated wells.
In vivo toxicology data
[0169] The HEDC:S104 (20:20) formulation of the present description is exceptionally well tolerated as shown in toxicity studies. No toxicity was observed when the formulation was injected intravenously in rats and monkey at doses up to 25 mg/kg and 12 mg/kg, respectively, which is considered by those skilled in the art to be superior.
Transfection with formulations of the description:
[0170] Transfection method is same for LX-2 and pHSCs. The liposome formulations or lipoplex formulations of the description were mixed with growth medium at desired concentrations. 100 μΐ of the mixture was added to the cells in 96-well plate and cells were incubated for 30 min at 37 °C in the incubator with 5% C02. After 30 min, medium was replaced with fresh growth medium. After 48 h of transfection, cells were processed using Cell-to-Ct lysis reagents (Applied Biosystems) according to the manufacturer's instructions. Quantitatve (q) RT-PCR for measuring HSP47 mRNA expression
[0171] HSP47 and GAPDH TaqMan® ® assays and One-Step RT-PCR master mix were purchased from Applied Biosystems. Each PCR reaction contained the following composition: One-step RT-PCR mix 5 μΐ, TaqMan® RT enzyme mix 0.25 μΐ, TaqMan® gene expression assay probe (HSP47) 0.25 μΐ, TaqMan® gene expression assay probe (GAPDH) 0.5 μΐ, RNase free water 3.25 μΐ, Cell lysate 0.75 μΐ, Total volume of 10 μΐ. GAPDH was used as endogenous control for the relative quantification of HSP47 mRNA levels. Quantitative RT-PCR was performed in ViiA 7 realtime PCR system (Applied Biosciences). All values were normalized to the average HSP47 expression of the mock transfected cells and expressed as percentage of HSP47 expression compared to mock.

Claims

What is Claimed:
1. A ionizable lipid compound of formula I:
Figure imgf000055_0001
wherein
n and m are independently I, 2, 3, or 4;
Ri and R2 are independently Cio-isalkyl or
Figure imgf000055_0002
X is -CH2-, S, O, N, or absent;
-0-C(0)-Ci_4alkylene,
Figure imgf000055_0003
or a pharmaceutically acceptable salt form thereof. The compound of claim 1 , wherein n and m are 1. The compound of claim I , wherein n and m are 2. The compound of claim I, wherein X is absent. The compound of claim 4, wherein L is Ci-4alkylene.
The compound of claim 5, wherein L is selected from the group consisting of
CH2-CH2-, -CH2-CH2CH2-, and -CH2-CH2CH2CH2-.
The compound of claim 4, wherein L is
Figure imgf000055_0004
The compound of claim 7, wherein L is
Figure imgf000056_0001
9. The compound of claim 1, wherein X is -CH2-.
10. The compound of claim 9, wherein L is -S-Ci-4alkylene.
1 1. The compound of claim 10, wherein L is -S-CH2- or -S-CH2-CH2-.
12. The compound of claim 9, wherein L is -S(0)2-Ci_4alkylene.
13. The compound of claim 12, wherein L is -S(0)2-CH2-CH2-.
14. The compound of claim 9, wherein L is -0-Ci-4alkylene.
15. The compound of claim 14, wherein L is -0-CH2-CH2- or -0-CH2-CH2-CH2-
16. The compound of claim 9, wherein L is -0-C(0)-C1-4alkylene.
17. The compound of claim 16, wherein L is -0-C(0)-CH2-CH2-CH2-.
18. The compound of claim 1, wherein X is S.
19. The compound of claim 18, wherein L is Ci-4alkylene.
20. The compound of claim 19, wherein L is -CH2-CH2-.
21. The compound of claim 1, wherein X is O.
22. The compound of claim 21, wherein L is Ci-4alkylene.
23. The compound of claim 22, wherein L is -CH2-CH2- or -CH2-CH2-CH2-.
24. The compound of claim 1, wherein Ri and R2 are each Cio isalkyl.
25. The compound of claim 24, wherein Ri and R2 are each C^alkyl.
26. The compound of claim 1, wherein Ri and I¾ are each
Figure imgf000057_0001
27. The compound of claim 26, wherein Ri and R2 are each Ci3-i7alkenyl.
28. The compound of claim 27, wherein Ri and R2 are each oleyl or linoleyl.
29. A composition comprising a cationic lipid and an ionizable cationic lipid in a
liposome comprising a bilayer of lipid molecules.
30. A composition comprising a compound of claim 1 in a liposome comprising a bilayer of lipid molecules.
31. The composition of claim 30, wherein the compound is 5 to 50 mol % of the lipid molecules.
32. The composition of claim 31, comprising two compounds of any one of claims 1-34 and wherein the molar ratio of the two compounds is about 10:30 to about 30: 10.
33. The composition of claim 31, further comprising a cationic lipid.
34. The composition of claim 33, wherein the cationic lipid is
Figure imgf000057_0002
or
Figure imgf000057_0003
HEDODC.
35. The composition of claim 33, wherein the cationic lipid is 5 to 40 mol % of the lipid molecules.
36. The composition of claim 35, wherein the molar ratio of the ionizable lipid and the cationic lipid is about 5:35 to about 35:5.
37. The composition of claim 30, further comprising a liquid medium.
38. The composition of claim 37, wherein the liquid medium is suitable for injection into a living organism.
39. The composition of claim 37, wherein the liquid medium comprises an organic
solvent.
40. The composition of claim 37, wherein the liquid medium comprises water and an organic solvent.
41. The composition of claim 30, further comprising a non-aqueous medium.
42. The composition of claim 30 further comprising at least one phospholipid.
43. The composition of claim 30, further comprising at least one PEG-conjugated lipid.
44. A stellate-cell-specific drug carrier comprising the composition of claim 30, and a stellate cell specific amount of a targeting molecule consisting of the structure (retinoid)n-linker-(retinoid)n, wherein n=0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule.
45. The drug carrier of claim 44, further comprising a siRNA molecule.
46. A pharmaceutical formulation comprising the drug carrier of claim 45 and a
pharmaceutically acceptable carrier or diluent.
47. The pharmaceutical formulation of claim 45, wherein the siRNA is encapsulated by the liposome. A method of delivering a drug to a patient comprising the pharmaceutical formulation of claim 47; and administering the pharmaceutical formulation to the patient.
PCT/US2013/044849 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations WO2013185116A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EP13729241.3A EP2858974B9 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
AU2013270685A AU2013270685B2 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
EP18200656.9A EP3489220B9 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
DK13729241.3T DK2858974T3 (en) 2012-06-08 2013-06-07 LIPIDS FOR THERAPEUTIC MEDICINE DELIVERY FORMULATIONS
RS20181385A RS58108B9 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
ES13729241T ES2697680T3 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent supply formulations
SI201331245T SI2858974T1 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
CA2876148A CA2876148C (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
BR112014030714-8A BR112014030714B1 (en) 2012-06-08 2013-06-07 ionizable lipid compound, composition, drug carrier and pharmaceutical formulation
PL18200656T PL3489220T3 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
LTEP13729241.3T LT2858974T (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
CN201380041854.8A CN104640841B (en) 2012-06-08 2013-06-07 Lipid for therapeutic agent delivering preparation
JP2015516267A JP5873604B2 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
PL13729241T PL2858974T3 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
KR1020157000454A KR102102801B1 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
RU2014153658A RU2658007C2 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations
HRP20181855TT HRP20181855T1 (en) 2012-06-08 2018-11-07 Lipids for therapeutic agent delivery formulations
CY181101255T CY1120929T1 (en) 2012-06-08 2018-11-27 LIPIDS FOR DISTRIBUTION RECOMMENDATIONS
CY20211100818T CY1124499T1 (en) 2012-06-08 2021-09-17 LIPIDS FOR THERAPEUTIC AGENT DELIVERY COMPOSITIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657480P 2012-06-08 2012-06-08
US61/657,480 2012-06-08

Publications (1)

Publication Number Publication Date
WO2013185116A1 true WO2013185116A1 (en) 2013-12-12

Family

ID=48626705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/044849 WO2013185116A1 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations

Country Status (22)

Country Link
US (3) US9308267B2 (en)
EP (2) EP3489220B9 (en)
JP (1) JP5873604B2 (en)
KR (1) KR102102801B1 (en)
CN (1) CN104640841B (en)
AU (1) AU2013270685B2 (en)
BR (1) BR112014030714B1 (en)
CA (1) CA2876148C (en)
CY (2) CY1120929T1 (en)
DK (2) DK2858974T3 (en)
ES (2) ES2897216T3 (en)
HR (2) HRP20211424T2 (en)
HU (2) HUE056014T2 (en)
LT (2) LT3489220T (en)
PL (2) PL3489220T3 (en)
PT (2) PT3489220T (en)
RS (2) RS58108B9 (en)
RU (1) RU2658007C2 (en)
SI (2) SI3489220T1 (en)
TR (1) TR201816986T4 (en)
TW (1) TWI654997B (en)
WO (1) WO2013185116A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081029A1 (en) * 2014-11-18 2016-05-26 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
US20160376229A1 (en) * 2015-06-24 2016-12-29 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
US9567296B2 (en) 2013-11-18 2017-02-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018084168A1 (en) 2016-11-02 2018-05-11 日東電工株式会社 Skin fibrosis treatment agent
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
WO2019074071A1 (en) 2017-10-11 2019-04-18 日東電工株式会社 Regulation of nucleic acid molecule expression
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10441659B2 (en) 2012-06-08 2019-10-15 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2022037652A1 (en) * 2020-08-20 2022-02-24 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022136641A1 (en) * 2020-12-23 2022-06-30 Etherna Immunotherapies Nv Ionizable lipids
WO2023044333A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
WO2023222870A1 (en) * 2022-05-20 2023-11-23 Etherna Immunotherapies Nv Ionizable lipids

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
RU2021109685A (en) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. VACCINES BASED ON NUCLEIC ACIDS
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180235995A1 (en) * 2015-02-19 2018-08-23 Nitto Denko Corporation Rna interference therapeutics against ebola virus
CA2990202A1 (en) * 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP6875373B2 (en) 2015-07-22 2021-05-26 日東電工株式会社 Compositions and Methods for Nanoparticle Freeze-Dried Forms
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
DK3394030T3 (en) 2015-12-22 2022-03-28 Modernatx Inc COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR RELEASE OF FUNDS
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
US9834510B2 (en) * 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3554546A4 (en) 2016-12-14 2021-04-14 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
JP7220154B2 (en) 2017-03-15 2023-02-09 モデルナティエックス インコーポレイテッド Crystalline forms of amino lipids
HUE060693T2 (en) 2017-03-15 2023-04-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP7275111B2 (en) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド Method for producing lipid nanoparticles
WO2019090359A1 (en) 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
CN108148870B (en) * 2018-01-12 2021-09-21 中国人民解放军第四军医大学 Method for improving siRNA transferring efficiency in vitro of chitosan
AU2019359299B2 (en) 2018-10-09 2022-04-21 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
CA3154618A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20230250056A1 (en) * 2020-06-24 2023-08-10 Bristol-Myers Squibb Company Process for synthesizing lipids
KR20230042022A (en) * 2020-06-24 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 Methods for synthesizing cationic lipids
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2023205424A2 (en) * 2022-04-21 2023-10-26 Greenlight Biosciences, Inc. Lipid compositions and methods for nucleic acid delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800818A1 (en) * 2010-04-28 2011-11-03 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2012170952A2 (en) * 2011-06-08 2012-12-13 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5994317A (en) * 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
CN1277024A (en) * 1999-06-11 2000-12-20 克林诺斯生物药品工业有限公司 Application of cationic liposome and polydeoxyribonucleosides composite using as medicament
CN101163796B (en) * 2004-06-07 2012-08-29 普洛体维生物治疗公司 Cationic lipids and methods of use
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
SI2730277T1 (en) 2004-12-22 2020-07-31 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
JP2006254877A (en) * 2005-03-18 2006-09-28 Fukuoka Prefecture Carrier containing glycolipid and method for transferring gene using the same
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (en) 2011-06-08 2019-05-11 日東電工股份有限公司 Retinoid-liposomes for enhancing modulation of hsp47 expression
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP2773328A2 (en) 2011-11-04 2014-09-10 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
TWI594723B (en) 2011-12-19 2017-08-11 愛爾康眼科手術激光股份有限公司 Image processor for intra-surgical optical coherence tomographic imaging of laser cataract procedures
EP3489220B9 (en) 2012-06-08 2021-11-10 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800818A1 (en) * 2010-04-28 2011-11-03 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2012170952A2 (en) * 2011-06-08 2012-12-13 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences, 18th Ed.,", 1990, MACK PUBLISHING CO.
FINGL ET AL.: "The Pharmacological Basis of Therapeutics", 1975, pages: 1
G. P. MOSS: "Biochemical Nomenclature and Related Documents," 2nd Ed.", 1992, PORTLAND PRESS, pages: 247 - 251

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103583B2 (en) 2012-06-08 2021-08-31 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US10441659B2 (en) 2012-06-08 2019-10-15 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US9567296B2 (en) 2013-11-18 2017-02-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9850202B2 (en) 2013-11-18 2017-12-26 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9580711B2 (en) 2013-11-18 2017-02-28 Arcturus Therapeutics, Inc. Lipid particles with asymmetric cationic lipids for RNA delivery
US9670152B2 (en) 2013-11-18 2017-06-06 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
USRE49233E1 (en) 2013-11-18 2022-10-04 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10781169B2 (en) 2013-11-18 2020-09-22 Arcturus Therapeutics, Inc. Method of synthesis of an ionizable cationic lipid
US10556861B2 (en) 2013-11-18 2020-02-11 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9896413B2 (en) 2013-11-18 2018-02-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10399937B2 (en) 2013-11-18 2019-09-03 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
AU2015350561B2 (en) * 2014-11-18 2020-01-30 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
JP2017535610A (en) * 2014-11-18 2017-11-30 アークトゥルス セラピューティクス， インコーポレイテッド Ionizable cationic lipids for RNA delivery
CN107207428A (en) * 2014-11-18 2017-09-26 阿克丘勒斯治疗公司 Ionizable cation lipid for RNA delivery
KR102380363B1 (en) * 2014-11-18 2022-03-29 아크투루스 쎄라퓨틱스, 인크. Ionizable cationic lipid for rna delivery
WO2016081029A1 (en) * 2014-11-18 2016-05-26 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
KR20170095241A (en) * 2014-11-18 2017-08-22 아크투루스 쎄라퓨틱스, 인크. Ionizable cationic lipid for rna delivery
US10167253B2 (en) * 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
US11384051B2 (en) 2015-06-24 2022-07-12 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
EP3686184A3 (en) * 2015-06-24 2020-08-26 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
AU2016281685B2 (en) * 2015-06-24 2021-08-12 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
US20190127318A1 (en) * 2015-06-24 2019-05-02 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
US20160376229A1 (en) * 2015-06-24 2016-12-29 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
WO2018084168A1 (en) 2016-11-02 2018-05-11 日東電工株式会社 Skin fibrosis treatment agent
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10980895B2 (en) 2016-12-21 2021-04-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2019074071A1 (en) 2017-10-11 2019-04-18 日東電工株式会社 Regulation of nucleic acid molecule expression
US10961188B2 (en) 2017-12-20 2021-03-30 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2022037652A1 (en) * 2020-08-20 2022-02-24 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022136641A1 (en) * 2020-12-23 2022-06-30 Etherna Immunotherapies Nv Ionizable lipids
WO2023044333A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
US11773061B2 (en) 2021-09-14 2023-10-03 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
WO2023222870A1 (en) * 2022-05-20 2023-11-23 Etherna Immunotherapies Nv Ionizable lipids

Also Published As

Publication number Publication date
RS62288B1 (en) 2021-09-30
US20200085957A1 (en) 2020-03-19
US9308267B2 (en) 2016-04-12
BR112014030714A2 (en) 2017-06-27
TR201816986T4 (en) 2019-01-21
CY1124499T1 (en) 2022-07-22
DK3489220T3 (en) 2021-09-06
TW201402146A (en) 2014-01-16
KR20150021566A (en) 2015-03-02
EP2858974B9 (en) 2022-07-20
EP3489220B9 (en) 2021-11-10
HUE056014T2 (en) 2022-01-28
RU2014153658A (en) 2016-07-27
JP2015523990A (en) 2015-08-20
HRP20181855T1 (en) 2018-12-28
ES2897216T3 (en) 2022-02-28
RS58108B1 (en) 2019-02-28
HUE041882T2 (en) 2019-06-28
EP3489220A1 (en) 2019-05-29
EP2858974B1 (en) 2018-10-17
EP2858974A1 (en) 2015-04-15
KR102102801B1 (en) 2020-04-22
CY1120929T1 (en) 2019-12-11
LT2858974T (en) 2018-12-10
ES2697680T9 (en) 2022-10-17
HRP20211424T2 (en) 2022-02-18
CA2876148C (en) 2021-01-12
RS58108B9 (en) 2022-11-30
RU2658007C2 (en) 2018-06-19
US20160074514A1 (en) 2016-03-17
JP5873604B2 (en) 2016-03-01
CA2876148A1 (en) 2013-12-12
US20130330401A1 (en) 2013-12-12
PT3489220T (en) 2021-10-22
CN104640841A (en) 2015-05-20
SI3489220T1 (en) 2021-11-30
PL2858974T3 (en) 2019-03-29
US11103583B2 (en) 2021-08-31
ES2697680T3 (en) 2019-01-25
LT3489220T (en) 2021-09-27
EP3489220B1 (en) 2021-08-18
PT2858974T (en) 2018-11-29
US10441659B2 (en) 2019-10-15
BR112014030714B1 (en) 2020-12-22
RS62288B9 (en) 2021-12-31
DK2858974T3 (en) 2018-12-03
HRP20211424T1 (en) 2022-02-04
CN104640841B (en) 2018-04-13
AU2013270685B2 (en) 2017-11-30
SI2858974T1 (en) 2019-01-31
AU2013270685A1 (en) 2015-01-29
TWI654997B (en) 2019-04-01
PL3489220T3 (en) 2021-11-02

Similar Documents

Publication Publication Date Title
US11103583B2 (en) Lipids for therapeutic agent delivery formulations
US11084779B2 (en) Cationic lipids for therapeutic agent delivery formulations
US10669229B2 (en) Compounds for targeting drug delivery and enhancing siRNA activity
WO2012170952A9 (en) Compounds for targeting drug delivery and enhancing sirna activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13729241

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2876148

Country of ref document: CA

Ref document number: 2015516267

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013729241

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157000454

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014153658

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013270685

Country of ref document: AU

Date of ref document: 20130607

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014030714

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014030714

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141208